Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: MAPK signaling pathway (mmu04010)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
1500003O
03Rik
KLA  ATP  ATP+KLA
 NM_019769 RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] KLA .92 .89 .89 .86 .85 .92 1.08
ATP 1.01 1.16 1.16 1.53 1.70 3.33 2.09
KLA/ATP .89 .97 .93 1.17 1.19 2.86 2.57
2010110P
09Rik
KLA  ATP  ATP+KLA
 NM_027363 RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] KLA .99 .98 1.02 .99 .94 1.01 1.01
ATP 1.04 1.05 .97 1.05 .95 .98 .95
KLA/ATP .93 1.00 1.02 .97 1.01 .96 .97
AK036998
KLA  ATP  ATP+KLA
 AK036998 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] KLA 1.43 1.09 .89 .79 .96 .97 .71
ATP 1.04 1.04 .71 .64 .90 .82 .82
KLA/ATP 1.34 1.23 1.01 .89 1.10 .82 .75
AK050363
KLA  ATP  ATP+KLA
 AK050363 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730040N22 product:unclassifiable, full insert sequence. [AK050363] KLA 1.00 .98 1.02 1.02 1.02 .92 .96
ATP .98 1.03 .93 .98 .96 1.02 .99
KLA/ATP 1.03 .96 .96 .95 1.02 .93 1.04
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Arrb1
KLA  ATP  ATP+KLA
 NM_177231 arrestin, beta 1 (Arrb1), transcript variant a, mRNA [NM_177231] KLA .41 .42 .32 .32 .31 .56 .80
ATP .97 .86 .81 .62 .47 .59 1.16
KLA/ATP .43 .37 .38 .36 .35 .35 .89
Atf2
KLA  ATP  ATP+KLA
 AK047405 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930056P03 product:activating transcription factor 2, full insert sequence. [AK047405] KLA 1.01 1.00 1.02 1.04 1.03 1.03 1.00
ATP .99 1.00 .95 1.01 1.04 .98 1.03
KLA/ATP 1.07 1.00 .98 .99 1.00 1.03 .93
Atf2
KLA  ATP  ATP+KLA
 NM_001025093 activating transcription factor 2 (Atf2), transcript variant 1, mRNA [NM_001025093] KLA 1.35 1.30 1.32 1.31 1.37 1.09 1.20
ATP 1.15 1.17 .99 1.11 1.22 1.39 1.28
KLA/ATP 1.38 1.42 1.21 1.28 1.17 1.33 1.69
Atf4
KLA  ATP  ATP+KLA
 NM_009716 activating transcription factor 4 (Atf4), mRNA [NM_009716] KLA .91 1.06 1.13 1.31 1.92 2.59 3.01
ATP 1.05 1.14 1.34 2.88 4.84 2.36 2.56
KLA/ATP 1.14 1.08 1.17 2.40 3.72 3.54 3.62
B230120H
23Rik
KLA  ATP  ATP+KLA
 NM_023057 RIKEN cDNA B230120H23 gene (B230120H23Rik), transcript variant 1, mRNA [NM_023057] KLA 1.35 1.36 1.17 .91 .69 .43 .56
ATP 1.01 1.12 .87 1.32 1.71 1.48 .63
KLA/ATP 1.37 1.46 .95 1.14 1.07 1.22 .78
B230120H
23Rik
KLA  ATP  ATP+KLA
 NM_178084 RIKEN cDNA B230120H23 gene (B230120H23Rik), transcript variant 2, mRNA [NM_178084] KLA 1.08 1.07 1.06 1.00 .87 .62 .68
ATP 1.11 1.24 1.41 1.31 1.49 1.04 .79
KLA/ATP 1.13 1.24 1.17 1.07 1.04 .89 .85
Bdnf
KLA  ATP  ATP+KLA
 NM_007540 brain derived neurotrophic factor (Bdnf), transcript variant 1, mRNA [NM_007540] KLA 1.00 1.01 1.01 1.01 1.01 1.00 .99
ATP 1.00 1.00 1.00 1.01 .99 .99 1.01
KLA/ATP 1.00 1.01 1.01 1.02 1.03 1.03 .98
BG242006
KLA  ATP  ATP+KLA
 BG242006 gb|602354740F1 NCI_CGAP_Mam1 Mus musculus cDNA clone IMAGE:4483064 5. [BG242006] KLA 2.25 2.23 2.26 2.70 2.56 2.67 1.45
ATP .92 .87 1.11 .97 .99 .97 .72
KLA/ATP 1.91 2.04 2.51 2.08 1.99 1.15 .67
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Cacna1a
KLA  ATP  ATP+KLA
 NM_007578 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] KLA .71 .66 .61 .63 .60 .71 .72
ATP 1.07 1.04 .89 1.08 .71 .56 .75
KLA/ATP .71 .72 .85 .69 .64 .63 .68
Cacna1b
KLA  ATP  ATP+KLA
 U04999 N-type calcium channel alpha1 subunit mRNA, complete cds [U04999] KLA .94 .94 .95 .88 1.09 .85 .92
ATP 1.06 1.17 1.00 1.24 1.59 1.15 1.17
KLA/ATP .91 .91 .95 .95 .90 .97 1.01
Cacna1d
KLA  ATP  ATP+KLA
 NM_001083616 calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 2, mRNA [NM_001083616] KLA 1.57 1.58 2.50 3.62 4.55 2.93 .99
ATP 1.12 .99 .97 .94 .75 1.71 1.48
KLA/ATP 1.47 1.51 1.82 1.56 1.67 2.93 4.60
Cacna1d
KLA  ATP  ATP+KLA
 NM_028981 calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 1, mRNA [NM_028981] KLA 1.20 1.26 1.43 1.62 2.07 1.66 1.00
ATP 1.03 1.03 .97 .97 .93 1.20 1.26
KLA/ATP 1.16 1.12 1.10 1.14 1.08 1.44 2.56
Cacna1e
KLA  ATP  ATP+KLA
 NM_009782 calcium channel, voltage-dependent, R type, alpha 1E subunit (Cacna1e), mRNA [NM_009782] KLA 1.01 .96 1.00 1.00 1.02 .99 1.04
ATP 1.03 .96 .95 1.01 1.02 1.02 1.00
KLA/ATP 1.01 1.01 1.00 1.04 .97 1.03 1.00
Cacna1f
KLA  ATP  ATP+KLA
 NM_019582 calcium channel, voltage-dependent, alpha 1F subunit (Cacna1f), mRNA [NM_019582] KLA 1.03 .98 1.05 1.06 1.00 1.02 1.01
ATP 1.05 1.05 .95 .98 .97 .96 1.01
KLA/ATP 1.01 1.03 .94 1.01 1.01 1.00 .99
Cacna1g
KLA  ATP  ATP+KLA
 NM_009783 calcium channel, voltage-dependent, T type, alpha 1G subunit (Cacna1g), transcript variant 1, mRNA [NM_009783] KLA .98 .96 .95 1.02 .99 1.03 1.01
ATP .95 .98 1.03 1.00 1.01 1.01 1.01
KLA/ATP 1.00 .97 .93 .99 .94 1.00 1.06
Cacna1h
KLA  ATP  ATP+KLA
 NM_021415 calcium channel, voltage-dependent, T type, alpha 1H subunit (Cacna1h), mRNA [NM_021415] KLA 1.07 1.00 1.04 1.01 1.02 .98 1.06
ATP .97 .96 1.05 1.00 1.00 .96 .99
KLA/ATP 1.00 .99 .96 .98 .96 .97 .92
Cacna1i
KLA  ATP  ATP+KLA
 NM_001044308 calcium channel, voltage-dependent, alpha 1I subunit (Cacna1i), mRNA [NM_001044308] KLA 1.02 .96 1.01 .98 1.00 1.05 .90
ATP .98 1.00 1.05 .98 1.04 .95 .99
KLA/ATP .97 .94 1.02 1.03 1.03 1.03 1.01
Cacna1s
KLA  ATP  ATP+KLA
 NM_001081023 calcium channel, voltage-dependent, L type, alpha 1S subunit (Cacna1s), mRNA [NM_001081023] KLA 1.03 1.01 .96 1.06 1.00 1.00 1.05
ATP 1.01 .98 1.02 1.02 1.05 1.07 1.05
KLA/ATP .99 1.05 1.02 1.05 1.03 1.05 1.00
Cacna2d1
KLA  ATP  ATP+KLA
 AK046959 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930007O16 product:calcium channel, voltage-dependent, alpha2/delta subunit 1, full insert sequence. [AK046959] KLA 1.04 1.01 .94 .95 1.04 1.05 1.05
ATP 1.06 .98 .99 1.04 1.02 1.00 1.05
KLA/ATP 1.04 1.01 .99 1.04 .99 1.01 .99
Cacna2d1
KLA  ATP  ATP+KLA
 NM_009784 calcium channel, voltage-dependent, alpha2/delta subunit 1 (Cacna2d1), transcript variant e, mRNA [NM_009784] KLA 1.02 1.02 1.02 1.00 1.03 1.01 1.02
ATP .99 .97 1.07 1.01 .99 .97 1.00
KLA/ATP 1.03 .99 1.01 1.04 1.03 1.01 .92
Cacna2d2
KLA  ATP  ATP+KLA
 NM_020263 calcium channel, voltage-dependent, alpha 2/delta subunit 2 (Cacna2d2), mRNA [NM_020263] KLA 1.03 1.04 1.03 .99 1.03 .93 .93
ATP 1.01 1.06 1.06 1.15 1.03 .99 .93
KLA/ATP 1.04 1.01 1.10 1.13 1.11 .97 .89
Cacna2d3
KLA  ATP  ATP+KLA
 NM_009785 calcium channel, voltage-dependent, alpha2/delta subunit 3 (Cacna2d3), mRNA [NM_009785] KLA 1.00 .98 1.07 .96 .99 .99 .99
ATP .99 .97 1.10 .99 1.00 .89 .97
KLA/ATP .95 1.04 1.00 .95 1.02 .99 .98
Cacna2d4
KLA  ATP  ATP+KLA
 AK030723 8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730412N02 product:hypothetical von Willebrand factor type A domain containing protein, full insert sequence. [AK030723] KLA .97 1.02 1.04 1.01 1.00 1.03 1.02
ATP 1.01 .93 1.03 1.01 .99 .99 1.01
KLA/ATP 1.03 .95 .87 .96 1.03 .97 1.05
Cacnb1
KLA  ATP  ATP+KLA
 NM_031173 calcium channel, voltage-dependent, beta 1 subunit (Cacnb1), transcript variant variant 1, mRNA [NM_031173] KLA 1.35 1.26 1.13 1.51 1.54 1.69 2.10
ATP 1.01 1.09 1.16 1.23 1.39 1.61 1.34
KLA/ATP 1.20 1.34 1.81 1.43 1.62 1.50 2.03
Cacnb2
KLA  ATP  ATP+KLA
 AK143332 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330008B16 product:calcium channel, voltage-dependent, beta 2 subunit, full insert sequence [AK143332] KLA 1.18 1.19 1.17 1.05 1.03 1.03 1.03
ATP .97 .91 1.02 1.07 .95 1.07 1.03
KLA/ATP 1.20 1.29 1.16 1.09 1.02 1.05 1.03
Cacnb2
KLA  ATP  ATP+KLA
 NM_023116 calcium channel, voltage-dependent, beta 2 subunit (Cacnb2), mRNA [NM_023116] KLA 1.23 1.15 1.47 1.25 1.02 1.02 1.05
ATP 1.00 1.01 .99 .99 1.02 1.01 1.01
KLA/ATP 1.21 1.27 1.12 1.24 .96 .98 1.02
Cacnb3
KLA  ATP  ATP+KLA
 NM_007581 calcium channel, voltage-dependent, beta 3 subunit (Cacnb3), transcript variant 1, mRNA [NM_007581] KLA 5.88 5.27 7.39 5.78 4.94 2.13 1.26
ATP 1.03 1.02 1.22 1.37 2.49 2.75 1.61
KLA/ATP 5.92 6.99 6.43 6.99 5.42 3.70 2.61
Cacnb4
KLA  ATP  ATP+KLA
 NM_001037099 calcium channel, voltage-dependent, beta 4 subunit (Cacnb4), transcript variant 1, mRNA [NM_001037099] KLA 1.07 1.11 1.17 1.11 1.15 1.13 1.07
ATP 1.00 1.00 1.03 1.06 1.21 1.17 1.50
KLA/ATP 1.13 1.12 1.15 1.16 1.35 1.69 1.32
Cacng1
KLA  ATP  ATP+KLA
 NM_007582 calcium channel, voltage-dependent, gamma subunit 1 (Cacng1), mRNA [NM_007582] KLA .98 .93 .99 .99 .96 .99 1.04
ATP 1.07 1.40 2.33 2.01 1.57 1.10 1.08
KLA/ATP 1.02 .94 .98 1.16 1.07 .98 1.05
Cacng2
KLA  ATP  ATP+KLA
 AK047238 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930041E13 product:hypothetical protein, full insert sequence [AK047238] KLA 1.18 1.18 1.12 1.11 1.10 1.17 1.35
ATP 1.03 .98 1.09 1.04 1.07 1.06 1.00
KLA/ATP 1.15 1.15 1.25 1.15 1.12 1.07 1.19
Cacng2
KLA  ATP  ATP+KLA
 NM_007583 calcium channel, voltage-dependent, gamma subunit 2 (Cacng2), mRNA [NM_007583] KLA 1.00 1.08 1.08 .95 1.07 1.09 1.03
ATP 1.04 1.05 1.05 1.04 1.00 1.02 .99
KLA/ATP 1.00 .98 1.02 1.09 1.06 1.07 1.03
Cacng3
KLA  ATP  ATP+KLA
 NM_019430 calcium channel, voltage-dependent, gamma subunit 3 (Cacng3), mRNA [NM_019430] KLA 1.07 1.09 1.00 .97 1.01 .94 .89
ATP 1.06 1.11 1.07 1.00 .98 .99 .97
KLA/ATP 1.07 1.06 1.03 .94 1.00 .99 .95
Cacng4
KLA  ATP  ATP+KLA
 AJ272045 mRNA for calcium channel gamma 4 subunit (CACNG4 gene) [AJ272045] KLA .99 .95 1.01 1.02 .98 1.09 .92
ATP .96 1.09 1.00 .95 .97 1.06 .95
KLA/ATP .97 1.01 1.04 .97 1.00 .96 .98
Cacng5
KLA  ATP  ATP+KLA
 NM_080644 calcium channel, voltage-dependent, gamma subunit 5 (Cacng5), mRNA [NM_080644] KLA .98 .99 .91 .98 1.02 .98 .98
ATP .96 1.02 .99 .99 1.05 1.04 .95
KLA/ATP .95 1.01 1.07 .99 1.02 .95 .99
Cacng6
KLA  ATP  ATP+KLA
 NM_133183 calcium channel, voltage-dependent, gamma subunit 6 (Cacng6), mRNA [NM_133183] KLA .95 .95 .94 1.03 .94 1.09 1.14
ATP 1.00 1.05 .95 1.05 .94 .93 .99
KLA/ATP 1.02 .98 .92 .97 1.02 .96 1.05
Cacng7
KLA  ATP  ATP+KLA
 NM_133189 calcium channel, voltage-dependent, gamma subunit 7 (Cacng7), mRNA [NM_133189] KLA 1.01 1.04 .98 1.01 1.00 1.05 1.02
ATP 1.05 1.03 .99 1.00 .98 .95 .98
KLA/ATP 1.00 .98 1.07 .99 .97 1.03 1.01
Cacng8
KLA  ATP  ATP+KLA
 NM_133190 calcium channel, voltage-dependent, gamma subunit 8 (Cacng8), mRNA [NM_133190] KLA 1.17 1.16 1.20 1.31 1.16 1.13 1.09
ATP .98 1.09 1.06 1.06 1.03 1.18 .99
KLA/ATP 1.27 1.35 1.29 1.09 1.04 1.06 1.19
Casp3
KLA  ATP  ATP+KLA
 NM_009810 caspase 3 (Casp3), mRNA [NM_009810] KLA 1.66 1.94 2.47 2.61 3.01 2.96 1.44
ATP .90 .99 1.17 1.30 1.01 1.17 .86
KLA/ATP 1.55 1.87 2.40 2.35 2.27 2.84 2.52
Casp3
KLA  ATP  ATP+KLA
 U49929 ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] KLA 1.71 1.87 2.69 3.11 3.64 3.42 1.52
ATP 1.04 1.07 1.16 1.34 .98 1.27 .86
KLA/ATP 1.80 1.96 2.46 2.91 2.50 3.24 3.10
Cd14
KLA  ATP  ATP+KLA
 NM_009841 CD14 antigen (Cd14), mRNA [NM_009841] KLA 2.35 2.68 2.54 2.21 2.39 1.52 1.57
ATP 1.44 2.28 2.82 3.98 6.68 16.14 6.92
KLA/ATP 2.92 3.79 3.96 5.12 5.29 10.42 11.50
Cdc25b
KLA  ATP  ATP+KLA
 NM_023117 cell division cycle 25 homolog B (S. pombe) (Cdc25b), transcript variant 1, mRNA [NM_023117] KLA .38 .34 .33 .34 .30 .31 .26
ATP .98 1.04 1.01 .89 .67 .58 .39
KLA/ATP .36 .33 .37 .40 .51 .43 .32
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Daxx
KLA  ATP  ATP+KLA
 NM_007829 Fas death domain-associated protein (Daxx), mRNA [NM_007829] KLA 13.43 12.31 10.74 10.71 8.02 8.78 4.52
ATP .88 .79 .74 .47 1.05 5.31 2.46
KLA/ATP 11.40 11.89 13.01 10.51 12.32 11.59 9.74
Ddit3
KLA  ATP  ATP+KLA
 NM_007837 DNA-damage inducible transcript 3 (Ddit3), mRNA [NM_007837] KLA .61 .59 .70 1.06 1.69 2.77 3.31
ATP .87 .65 .80 1.34 1.88 1.58 4.98
KLA/ATP .58 .51 .67 1.54 4.63 3.78 8.88
Dusp1
KLA  ATP  ATP+KLA
 NM_013642 dual specificity phosphatase 1 (Dusp1), mRNA [NM_013642] KLA 4.56 3.88 6.42 8.88 7.87 4.61 3.97
ATP 4.35 6.31 15.22 22.62 6.79 7.21 2.84
KLA/ATP 5.44 7.70 16.61 23.52 9.62 11.17 12.72
Dusp10
KLA  ATP  ATP+KLA
 NM_022019 dual specificity phosphatase 10 (Dusp10), mRNA [NM_022019] KLA 1.82 1.74 2.08 2.69 1.59 1.61 1.29
ATP .83 .87 1.73 4.48 11.77 9.59 2.67
KLA/ATP 1.53 1.59 2.07 4.99 10.11 14.05 6.90
Dusp14
KLA  ATP  ATP+KLA
 NM_019819 dual specificity phosphatase 14 (Dusp14), mRNA [NM_019819] KLA 2.40 2.24 1.97 1.51 1.14 1.17 1.09
ATP .95 .98 1.81 6.09 11.10 11.62 4.14
KLA/ATP 2.35 2.46 1.86 3.07 4.69 10.09 10.64
Dusp16
KLA  ATP  ATP+KLA
 AF345951 map kinase phosphatase-M A1 isoform mRNA, complete cds. [AF345951] KLA 5.69 5.60 5.88 5.66 4.01 2.22 2.25
ATP .96 .87 1.87 2.78 3.45 4.57 1.17
KLA/ATP 5.77 5.29 8.23 6.44 6.47 4.81 2.30
Dusp16
KLA  ATP  ATP+KLA
 NM_130447 dual specificity phosphatase 16 (Dusp16), transcript variant A1, mRNA [NM_130447] KLA 2.73 2.96 3.39 2.65 2.55 1.58 1.60
ATP 1.02 1.07 1.49 1.70 1.62 2.35 1.25
KLA/ATP 3.05 3.22 3.07 3.12 2.11 2.77 2.28
Dusp2
KLA  ATP  ATP+KLA
 NM_010090 dual specificity phosphatase 2 (Dusp2), mRNA [NM_010090] KLA 43.10 42.75 36.17 49.49 35.86 16.34 5.07
ATP .92 1.69 37.49 58.42 16.31 14.80 1.24
KLA/ATP 39.37 45.95 72.93 79.76 46.84 37.71 12.16
Dusp22
KLA  ATP  ATP+KLA
 NM_134068 dual specificity phosphatase 22 (Dusp22), transcript variant 2, mRNA [NM_134068] KLA .79 .76 .76 .68 .58 .63 .60
ATP 1.18 1.16 1.08 .97 .71 .41 .50
KLA/ATP .79 .76 .78 .85 .57 .36 .54
Dusp3
KLA  ATP  ATP+KLA
 NM_028207 dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) (Dusp3), mRNA [NM_028207] KLA .69 .71 .63 .72 .77 .83 .92
ATP 1.07 1.12 1.01 1.23 1.00 .85 2.22
KLA/ATP .70 .80 .65 .79 .77 .71 1.71
Dusp4
KLA  ATP  ATP+KLA
 AK012530 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700078F24 product:unclassifiable, full insert sequence [AK012530] KLA .27 .25 .25 .23 .25 .24 .41
ATP 1.19 1.15 2.70 5.70 5.30 1.74 1.44
KLA/ATP .25 .29 1.36 4.31 3.60 .81 .92
Dusp4
KLA  ATP  ATP+KLA
 NM_176933 dual specificity phosphatase 4 (Dusp4), mRNA [NM_176933] KLA .22 .22 .17 .26 .17 .24 .42
ATP 1.37 1.55 2.80 6.42 4.54 2.15 2.57
KLA/ATP .20 .28 .93 3.44 2.59 .72 1.83
Dusp6
KLA  ATP  ATP+KLA
 NM_026268 dual specificity phosphatase 6 (Dusp6), mRNA [NM_026268] KLA .10 .08 .09 .08 .12 .25 .16
ATP 1.03 .73 .90 .43 .08 .40 .46
KLA/ATP .09 .07 .12 .13 .07 .11 .21
Dusp7
KLA  ATP  ATP+KLA
 NM_153459 dual specificity phosphatase 7 (Dusp7), mRNA [NM_153459] KLA .19 .18 .28 .42 .50 .39 .38
ATP .98 .95 .88 .86 1.24 .39 .86
KLA/ATP .17 .17 .25 .31 .47 .42 .34
Dusp8
KLA  ATP  ATP+KLA
 NM_008748 dual specificity phosphatase 8 (Dusp8), mRNA [NM_008748] KLA .80 .74 .62 .75 .65 .86 1.60
ATP .92 .91 2.28 4.12 1.71 .95 1.13
KLA/ATP .76 .67 .84 1.44 1.46 1.03 1.58
Dusp9
KLA  ATP  ATP+KLA
 NM_029352 dual specificity phosphatase 9 (Dusp9), mRNA [NM_029352] KLA .84 .80 .83 .75 .67 .71 .85
ATP 1.01 .99 .89 .94 .94 .83 .81
KLA/ATP .85 .90 .87 .81 .67 .59 .81
Ecsit
KLA  ATP  ATP+KLA
 NM_012029 ECSIT homolog (Drosophila) (Ecsit), mRNA [NM_012029] KLA .63 .57 .52 .71 .75 .86 1.24
ATP .98 .86 .84 .81 .72 .88 1.18
KLA/ATP .63 .57 .68 .52 .52 .78 .78
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Elk1
KLA  ATP  ATP+KLA
 AK082260 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] KLA 1.02 1.01 1.01 .97 1.00 1.03 1.06
ATP 1.02 1.07 1.06 1.03 1.02 1.02 1.00
KLA/ATP 1.08 .99 .97 1.01 1.02 1.06 .95
Elk4
KLA  ATP  ATP+KLA
 AK037559 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026I01 product:unclassifiable, full insert sequence. [AK037559] KLA 1.04 .93 .96 .94 .99 1.06 .93
ATP .95 .98 .89 .92 .96 1.00 .96
KLA/ATP .94 .94 .99 .92 .93 .99 .96
Elk4
KLA  ATP  ATP+KLA
 NM_007923 ELK4, member of ETS oncogene family (Elk4), mRNA [NM_007923] KLA .96 1.04 1.07 1.04 1.05 1.01 1.09
ATP .93 1.01 1.02 1.01 1.00 1.10 1.01
KLA/ATP .98 1.01 .94 1.02 1.03 1.04 1.04
Evi1
KLA  ATP  ATP+KLA
 BC076620 ecotropic viral integration site 1, mRNA (cDNA clone IMAGE:30645345), partial cds [BC076620] KLA 1.04 .98 1.05 .96 1.09 1.04 .92
ATP .94 .96 1.11 1.00 1.03 1.08 1.14
KLA/ATP 1.00 .92 1.02 1.12 1.06 1.00 1.08
Evi1
KLA  ATP  ATP+KLA
 NM_007963 ecotropic viral integration site 1 (Evi1), mRNA [NM_007963] KLA .93 .99 1.04 1.02 1.05 1.11 1.10
ATP .96 .96 .98 1.03 1.03 .85 1.02
KLA/ATP 1.04 .95 .97 1.01 1.10 1.09 .99
Fas
KLA  ATP  ATP+KLA
 AK086933 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] KLA 6.31 6.56 6.33 6.70 4.93 3.74 2.48
ATP .95 1.04 1.33 1.55 1.85 6.00 2.77
KLA/ATP 5.67 7.16 7.71 7.73 6.02 5.79 7.85
Fas
KLA  ATP  ATP+KLA
 NM_007987 Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] KLA 17.08 17.45 19.08 17.38 13.33 6.78 4.46
ATP .98 .96 1.64 3.05 5.58 12.91 1.89
KLA/ATP 16.57 17.25 26.06 23.57 22.03 16.74 13.29
Fasl
KLA  ATP  ATP+KLA
 NM_010177 Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] KLA 1.03 1.01 1.03 1.02 1.01 1.01 1.00
ATP 1.00 .99 1.04 1.21 1.18 1.20 1.01
KLA/ATP 1.00 1.02 1.07 1.16 1.18 1.23 1.00
Fgf1
KLA  ATP  ATP+KLA
 NM_010197 fibroblast growth factor 1 (Fgf1), mRNA [NM_010197] KLA 1.07 .99 .99 1.00 1.03 .97 .99
ATP 1.01 1.03 1.01 .95 .95 .98 .88
KLA/ATP 1.03 .99 .97 .99 .98 .94 1.01
Fgf10
KLA  ATP  ATP+KLA
 NM_008002 fibroblast growth factor 10 (Fgf10), mRNA [NM_008002] KLA .99 .98 1.02 1.00 1.02 1.02 1.02
ATP 1.03 1.02 1.00 1.00 1.00 .99 .99
KLA/ATP 1.01 1.00 1.04 .99 1.00 1.02 1.01
Fgf11
KLA  ATP  ATP+KLA
 BC066859 fibroblast growth factor 11, mRNA (cDNA clone MGC:76712 IMAGE:30101881), complete cds [BC066859] KLA .64 .61 .55 .58 .51 .48 .77
ATP 1.00 .96 .78 .78 .63 .44 .48
KLA/ATP .64 .63 .59 .56 .54 .42 .40
Fgf11
KLA  ATP  ATP+KLA
 NM_010198 fibroblast growth factor 11 (Fgf11), mRNA [NM_010198] KLA .99 1.02 1.05 1.04 1.01 1.03 1.07
ATP .95 1.02 1.02 1.07 .98 1.01 1.07
KLA/ATP 1.01 1.01 1.08 .96 .97 .95 1.01
Fgf12
KLA  ATP  ATP+KLA
 NM_183064 fibroblast growth factor 12 (Fgf12), transcript variant 1, mRNA [NM_183064] KLA .96 .97 1.05 .99 .97 1.01 1.01
ATP .93 .97 .97 .97 .99 .95 1.00
KLA/ATP 1.02 1.05 1.10 1.02 .95 1.01 .95
Fgf13
KLA  ATP  ATP+KLA
 NM_010200 fibroblast growth factor 13 (Fgf13), mRNA [NM_010200] KLA .91 .92 .93 .84 .77 .66 .75
ATP 1.09 1.14 1.03 1.11 1.06 .68 .78
KLA/ATP .98 1.02 .86 .90 .78 .70 .79
Fgf14
KLA  ATP  ATP+KLA
 NM_010201 fibroblast growth factor 14 (Fgf14), transcript variant 1, mRNA [NM_010201] KLA 1.04 1.05 1.02 1.04 1.03 1.05 1.03
ATP .99 1.08 1.04 1.00 .99 .98 1.04
KLA/ATP 1.00 1.00 1.08 1.00 1.04 1.01 1.03
Fgf14
KLA  ATP  ATP+KLA
 NM_207667 fibroblast growth factor 14 (Fgf14), transcript variant 2, mRNA [NM_207667] KLA 1.04 1.01 .98 .93 .96 .96 .97
ATP 1.04 1.10 .94 .87 1.03 .99 .96
KLA/ATP .86 .94 1.03 .89 1.00 .90 1.03
Fgf15
KLA  ATP  ATP+KLA
 NM_008003 fibroblast growth factor 15 (Fgf15), mRNA [NM_008003] KLA 1.00 1.00 .95 .98 .92 .96 1.01
ATP .99 1.01 .98 .98 .93 .95 .97
KLA/ATP .98 1.01 1.02 1.03 .97 .97 1.00
Fgf16
KLA  ATP  ATP+KLA
 NM_030614 fibroblast growth factor 16 (Fgf16), mRNA [NM_030614] KLA 1.00 .97 .99 1.02 1.04 .97 .97
ATP 1.02 .99 .99 1.02 1.12 1.01 1.02
KLA/ATP 1.06 1.02 .99 1.01 1.00 1.10 1.03
Fgf17
KLA  ATP  ATP+KLA
 NM_008004 fibroblast growth factor 17 (Fgf17), mRNA [NM_008004] KLA .97 1.03 .98 1.00 .97 .97 .86
ATP .99 .96 .99 .90 1.02 1.01 1.01
KLA/ATP .99 .91 1.08 .99 .99 .98 .99
Fgf18
KLA  ATP  ATP+KLA
 NM_008005 fibroblast growth factor 18 (Fgf18), mRNA [NM_008005] KLA 1.17 1.18 1.16 1.12 1.03 1.13 1.04
ATP .96 .98 2.47 12.57 2.76 1.56 1.03
KLA/ATP 1.01 1.15 2.33 10.13 2.80 1.79 1.02
Fgf2
KLA  ATP  ATP+KLA
 NM_008006 fibroblast growth factor 2 (Fgf2), mRNA [NM_008006] KLA 1.02 1.01 1.00 1.03 1.01 1.02 1.01
ATP .99 1.01 1.00 1.02 1.01 1.01 1.00
KLA/ATP 1.00 1.01 .98 1.01 1.02 1.03 1.01
Fgf20
KLA  ATP  ATP+KLA
 NM_030610 fibroblast growth factor 20 (Fgf20), mRNA [NM_030610] KLA .97 1.08 .99 1.00 .97 1.00 .97
ATP 1.03 .95 .97 1.05 .98 .97 1.00
KLA/ATP .99 .99 1.06 1.04 1.02 .92 .96
Fgf21
KLA  ATP  ATP+KLA
 NM_020013 fibroblast growth factor 21 (Fgf21), mRNA [NM_020013] KLA 1.02 1.03 .87 1.04 1.00 1.01 1.00
ATP 1.04 .97 1.00 1.02 .96 1.05 1.02
KLA/ATP 1.08 1.00 1.00 1.00 1.03 1.02 .99
Fgf22
KLA  ATP  ATP+KLA
 AK008922 adult male stomach cDNA, RIKEN full-length enriched library, clone:2210414E06 product:FIBROBLAST GROWTH FACTOR-22 PRECURSOR (FGF-22) homolog [Mus musculus], full insert sequence [AK008922] KLA .90 .94 .95 1.04 1.03 .94 .97
ATP 1.04 1.01 .98 .93 .93 .95 .88
KLA/ATP .98 .97 .97 1.01 .95 .92 .95
Fgf22
KLA  ATP  ATP+KLA
 NM_023304 fibroblast growth factor 22 (Fgf22), mRNA [NM_023304] KLA .99 .94 1.01 .95 .97 .89 .99
ATP 1.00 .95 1.00 .96 .97 .93 .98
KLA/ATP .91 1.00 1.01 .92 .95 .98 .97
Fgf23
KLA  ATP  ATP+KLA
 NM_022657 fibroblast growth factor 23 (Fgf23), mRNA [NM_022657] KLA 1.32 1.39 1.27 1.22 1.07 1.03 1.14
ATP .95 1.00 1.05 1.07 1.05 1.02 .96
KLA/ATP 1.32 1.39 1.37 1.22 1.01 1.00 .90
Fgf3
KLA  ATP  ATP+KLA
 NM_008007 fibroblast growth factor 3 (Fgf3), mRNA [NM_008007] KLA 1.03 1.05 1.00 .97 1.01 .98 .97
ATP 1.01 1.00 .97 1.03 .98 1.03 .97
KLA/ATP .98 1.00 1.01 1.03 1.03 1.00 .99
Fgf5
KLA  ATP  ATP+KLA
 NM_010203 fibroblast growth factor 5 (Fgf5), mRNA [NM_010203] KLA 1.02 1.02 1.00 1.03 .97 1.05 .99
ATP 1.02 1.00 1.03 .97 .99 .97 1.04
KLA/ATP 1.05 .92 1.01 1.00 1.11 .96 .97
Fgf6
KLA  ATP  ATP+KLA
 M92416 fibroblast growth factor (Fgf6) mRNA, 3 end [M92416] KLA 1.09 1.07 1.00 1.06 .97 1.01 .96
ATP 1.02 1.02 1.06 1.02 .93 .99 .98
KLA/ATP 1.04 .99 1.00 .99 1.00 1.00 1.03
Fgf6
KLA  ATP  ATP+KLA
 NM_010204 fibroblast growth factor 6 (Fgf6), mRNA [NM_010204] KLA 1.00 .96 1.06 .96 .96 1.00 .91
ATP .94 1.00 .89 .95 1.01 .92 1.00
KLA/ATP .99 1.06 1.06 .86 1.00 .95 1.00
Fgf7
KLA  ATP  ATP+KLA
 NM_008008 fibroblast growth factor 7 (Fgf7), mRNA [NM_008008] KLA 1.02 1.02 1.02 1.03 1.05 1.11 1.04
ATP 1.00 1.01 1.11 1.15 1.05 1.04 1.06
KLA/ATP .99 .96 .83 1.10 1.15 1.26 1.21
Fgf8
KLA  ATP  ATP+KLA
 BC048734 fibroblast growth factor 8, mRNA (cDNA clone MGC:59627 IMAGE:6513131), complete cds [BC048734] KLA .96 .95 1.03 .96 1.06 .97 .96
ATP 1.08 .94 1.07 1.10 1.00 .93 1.06
KLA/ATP 1.03 1.02 1.04 .96 1.04 .94 .94
Fgf8
KLA  ATP  ATP+KLA
 NM_010205 fibroblast growth factor 8 (Fgf8), mRNA [NM_010205] KLA 1.00 1.00 1.03 1.04 1.04 1.07 1.09
ATP 1.01 1.01 1.11 1.14 1.11 1.09 1.05
KLA/ATP 1.00 1.04 1.14 1.18 1.15 1.09 1.04
Fgf9
KLA  ATP  ATP+KLA
 NM_013518 fibroblast growth factor 9 (Fgf9), mRNA [NM_013518] KLA 1.04 1.07 1.07 1.12 .97 .96 .91
ATP 1.02 1.08 .98 1.00 .94 .99 .92
KLA/ATP 1.04 1.03 1.03 1.00 .93 .93 .89
Fgfr1
KLA  ATP  ATP+KLA
 M28998 gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] KLA .82 .79 .73 .66 .50 .55 .65
ATP 1.01 1.08 .86 .90 1.29 1.24 1.52
KLA/ATP .85 .82 .71 .71 .63 .80 .85
Fgfr1
KLA  ATP  ATP+KLA
 NM_010206 fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] KLA .92 .86 .73 .82 .79 .85 .84
ATP 1.01 1.06 .92 .92 1.18 1.02 1.22
KLA/ATP .83 .83 .79 .76 .83 .83 .92
Fgfr2
KLA  ATP  ATP+KLA
 NM_010207 fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] KLA 1.01 .98 1.00 1.01 .98 1.00 .99
ATP 1.00 1.03 1.05 1.03 1.01 1.01 1.00
KLA/ATP 1.00 1.01 1.04 1.01 .99 1.02 1.03
Fgfr3
KLA  ATP  ATP+KLA
 NM_008010 fibroblast growth factor receptor 3 (Fgfr3), mRNA [NM_008010] KLA 1.09 1.15 1.05 1.10 1.02 1.05 1.12
ATP 1.05 .94 .98 .87 .91 .95 .92
KLA/ATP 1.13 1.11 1.10 .91 .92 .93 .92
Fgfr4
KLA  ATP  ATP+KLA
 AF127140 fibroblast growth factor receptor 4 splice variant 17b (Fgfr4) mRNA, partial cds. [AF127140] KLA .96 .97 1.06 .97 1.05 1.05 1.08
ATP 1.02 .98 1.07 1.23 1.15 1.18 1.31
KLA/ATP .91 1.02 1.08 1.16 1.07 1.05 1.23
Fgfr4
KLA  ATP  ATP+KLA
 NM_008011 fibroblast growth factor receptor 4 (Fgfr4), mRNA [NM_008011] KLA 1.08 1.11 1.09 1.06 .99 1.06 1.03
ATP 1.05 .96 1.17 1.06 1.10 1.04 1.01
KLA/ATP 1.03 .98 1.10 1.06 1.05 1.06 1.04
Flna
KLA  ATP  ATP+KLA
 AK044856 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130008E07 product:hypothetical Calponin homology (CH) domain containing protein, full insert sequence. [AK044856] KLA .95 .95 1.00 .99 1.02 1.10 1.00
ATP .93 .94 1.02 1.08 1.04 1.01 .99
KLA/ATP 1.02 .98 .99 .98 1.02 1.08 1.02
Flna
KLA  ATP  ATP+KLA
 NM_010227 filamin, alpha (Flna), mRNA [NM_010227] KLA .90 .91 .92 .83 1.03 1.12 .82
ATP 1.02 1.06 .77 .69 .58 .69 .72
KLA/ATP .97 .90 .69 .66 .49 .59 .83
Flnb
KLA  ATP  ATP+KLA
 AK050046 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730006K15 product:filamin, beta, full insert sequence. [AK050046] KLA 5.58 4.67 5.09 3.71 3.12 1.55 1.22
ATP .97 1.04 1.40 1.56 2.09 1.87 1.06
KLA/ATP 6.20 5.77 5.48 4.31 2.53 2.35 1.37
Flnb
KLA  ATP  ATP+KLA
 NM_134080 filamin, beta (Flnb), mRNA [NM_134080] KLA 8.86 8.95 10.89 9.75 10.94 7.28 1.54
ATP 1.03 1.08 1.17 1.39 1.82 2.72 1.01
KLA/ATP 8.89 10.37 11.36 10.83 7.90 5.59 3.36
Flnc
KLA  ATP  ATP+KLA
 AK051985 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230030L22 product:weakly similar to CGABP260 ACTIN-BINDING DOMAIN (FRAGMENT) [Gallus gallus], full insert sequence. [AK051985] KLA .97 1.04 1.01 1.03 1.01 1.05 1.06
ATP 1.02 1.04 1.00 1.02 1.02 1.10 1.06
KLA/ATP 1.00 1.00 .98 1.07 1.03 1.07 1.04
Flnc
KLA  ATP  ATP+KLA
 NM_001081185 filamin C, gamma (actin binding protein 280) (Flnc), mRNA [NM_001081185] KLA .95 1.00 1.02 1.00 .95 .98 1.05
ATP 1.02 1.01 1.11 1.37 1.04 1.04 1.13
KLA/ATP .99 1.02 .93 1.00 .90 .99 1.03
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Gadd45a
KLA  ATP  ATP+KLA
 NM_007836 growth arrest and DNA-damage-inducible 45 alpha (Gadd45a), mRNA [NM_007836] KLA .52 .72 .68 .82 1.11 .73 1.91
ATP .92 .85 1.20 3.38 7.86 3.35 3.64
KLA/ATP .54 .95 1.60 3.49 5.04 3.79 2.80
Gadd45b
KLA  ATP  ATP+KLA
 NM_008655 growth arrest and DNA-damage-inducible 45 beta (Gadd45b), mRNA [NM_008655] KLA 10.08 11.65 8.40 11.27 8.24 7.30 5.74
ATP 1.83 3.28 10.08 27.60 15.97 8.84 4.61
KLA/ATP 9.36 14.99 21.30 45.24 49.27 21.63 22.73
Gadd45g
KLA  ATP  ATP+KLA
 NM_011817 growth arrest and DNA-damage-inducible 45 gamma (Gadd45g), mRNA [NM_011817] KLA 2.18 2.14 2.95 3.62 3.22 4.69 1.21
ATP 1.01 1.74 8.49 11.83 4.60 5.94 5.94
KLA/ATP 2.58 3.99 12.54 13.16 12.25 12.41 12.33
Gna12
KLA  ATP  ATP+KLA
 M63659 gb|Mouse G-alpha-12 protein mRNA, complete cds [M63659] KLA .48 .48 .49 .40 .44 .59 .60
ATP 1.08 1.15 1.00 1.39 1.02 .65 .73
KLA/ATP .52 .50 .51 .52 .56 .66 .52
Gng12
KLA  ATP  ATP+KLA
 NM_025278 guanine nucleotide binding protein (G protein), gamma 12 (Gng12), mRNA [NM_025278] KLA 2.21 2.23 2.48 2.62 2.47 2.28 1.68
ATP 1.02 1.02 1.09 1.10 1.20 1.32 1.01
KLA/ATP 2.10 2.17 2.38 2.40 1.91 1.60 1.77
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Hspa1a
KLA  ATP  ATP+KLA
 NM_010479 heat shock protein 1A (Hspa1a), mRNA [NM_010479] KLA 7.88 6.99 4.47 5.18 7.81 11.47 4.14
ATP 1.88 5.62 43.42 58.76 55.53 28.89 9.13
KLA/ATP 7.40 7.62 28.23 54.12 70.14 43.09 22.49
Hspa1b
KLA  ATP  ATP+KLA
 NM_010478 heat shock protein 1B (Hspa1b), mRNA [NM_010478] KLA 5.01 4.73 3.77 3.62 4.81 6.53 3.12
ATP 1.34 3.07 14.11 17.14 17.51 11.21 4.82
KLA/ATP 5.04 5.15 11.63 19.94 20.84 15.79 9.30
Hspa1l
KLA  ATP  ATP+KLA
 NM_013558 heat shock protein 1-like (Hspa1l), mRNA [NM_013558] KLA .98 1.04 1.10 1.21 1.51 1.97 1.86
ATP 1.03 1.08 1.07 1.14 .93 1.21 1.89
KLA/ATP 1.06 1.01 .99 1.09 .97 1.39 2.87
Hspa2
KLA  ATP  ATP+KLA
 NM_008301 heat shock protein 2 (Hspa2), transcript variant 1, mRNA [NM_008301] KLA .98 .97 1.12 1.23 1.20 1.72 1.38
ATP 1.01 1.10 1.45 3.12 2.45 1.98 .98
KLA/ATP .99 1.12 1.52 2.60 2.89 2.62 1.18
Hspa8
KLA  ATP  ATP+KLA
 NM_031165 heat shock protein 8 (Hspa8), mRNA [NM_031165] KLA 1.00 .98 1.27 1.18 1.45 1.60 1.31
ATP 1.22 1.18 1.07 1.44 1.07 .53 .57
KLA/ATP 1.18 1.22 1.14 1.08 .93 .82 .77
Hspb1
KLA  ATP  ATP+KLA
 NM_013560 heat shock protein 1 (Hspb1), mRNA [NM_013560] KLA 1.63 1.62 1.69 1.84 1.65 1.81 1.21
ATP 1.03 1.21 6.84 15.12 14.19 14.09 5.57
KLA/ATP 1.71 1.77 3.66 12.62 12.11 12.52 7.66
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Il1a
KLA  ATP  ATP+KLA
 NM_010554 interleukin 1 alpha (Il1a), mRNA [NM_010554] KLA 32.45 35.22 31.30 20.95 28.57 18.36 19.02
ATP 1.04 1.02 2.21 5.46 11.06 32.07 3.40
KLA/ATP 32.02 41.20 35.12 46.91 28.76 42.72 57.80
Il1b
KLA  ATP  ATP+KLA
 NM_008361 interleukin 1 beta (Il1b), mRNA [NM_008361] KLA 149.78 133.59 100.91 116.58 86.48 89.37 64.72
ATP 3.49 13.96 61.44 70.91 82.12 162.79 28.18
KLA/ATP 130.32 139.00 219.12 148.17 165.44 172.57 146.98
Il1r1
KLA  ATP  ATP+KLA
 NM_008362 interleukin 1 receptor, type I (Il1r1), transcript variant 1, mRNA [NM_008362] KLA 1.20 1.08 1.22 1.52 2.19 2.32 1.61
ATP 1.10 .96 1.18 1.56 8.14 9.56 7.54
KLA/ATP 1.22 1.13 1.37 1.85 4.54 6.85 8.96
Il1r2
KLA  ATP  ATP+KLA
 NM_010555 interleukin 1 receptor, type II (Il1r2), mRNA [NM_010555] KLA 1.05 1.03 1.08 1.13 1.09 1.08 1.14
ATP 1.03 1.08 1.30 1.68 1.38 1.10 1.19
KLA/ATP 1.08 1.14 1.17 1.27 1.10 1.11 2.03
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Jund
KLA  ATP  ATP+KLA
 NM_010592 Jun proto-oncogene related gene d (Jund), mRNA [NM_010592] KLA 1.56 1.42 1.33 1.15 1.00 .95 1.36
ATP 1.21 1.51 3.47 5.90 5.16 1.99 1.13
KLA/ATP 1.58 1.80 2.28 4.01 4.07 2.47 1.35
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
LOC10004
8021
KLA  ATP  ATP+KLA
 XM_001479354 ref|PREDICTED: Mus musculus similar to Guanine nucleotide-binding protein alpha-12 subunit (G alpha-12) (LOC100048021), mRNA [XM_001479354] KLA .29 .29 .23 .19 .25 .43 .47
ATP 1.03 1.08 .94 .88 .78 .52 .59
KLA/ATP .32 .29 .20 .22 .31 .47 .36
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k1ip
1
KLA  ATP  ATP+KLA
 NM_019920 mitogen-activated protein kinase kinase 1 interacting protein 1 (Map2k1ip1), mRNA [NM_019920] KLA .75 .74 .83 .96 .88 .95 .85
ATP 1.00 .82 1.17 1.01 1.84 1.42 1.37
KLA/ATP .69 .70 1.03 .79 1.54 1.34 1.05
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Map2k3
KLA  ATP  ATP+KLA
 NM_008928 mitogen-activated protein kinase kinase 3 (Map2k3), mRNA [NM_008928] KLA .88 .88 .73 .65 .99 1.34 .92
ATP 1.04 1.09 .89 1.62 1.93 1.75 1.17
KLA/ATP 1.00 .92 .66 1.21 1.80 2.24 2.10
Map2k4
KLA  ATP  ATP+KLA
 NM_009157 mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] KLA 3.67 3.75 4.23 3.90 3.30 1.87 1.12
ATP 1.05 1.11 1.04 .93 1.16 2.62 1.02
KLA/ATP 3.70 4.13 3.27 4.13 2.98 3.03 1.82
Map2k5
KLA  ATP  ATP+KLA
 NM_011840 mitogen-activated protein kinase kinase 5 (Map2k5), mRNA [NM_011840] KLA .80 .86 .78 .68 .75 .86 1.09
ATP .97 .90 .71 .85 .81 .98 .80
KLA/ATP .83 .73 .50 .56 .63 .98 .79
Map2k6
KLA  ATP  ATP+KLA
 NM_011943 mitogen-activated protein kinase kinase 6 (Map2k6), mRNA [NM_011943] KLA .68 .67 .64 .67 .62 .59 .61
ATP 1.02 1.12 1.04 1.10 .79 .61 .61
KLA/ATP .73 .69 .71 .74 .66 .62 .98
Map2k7
KLA  ATP  ATP+KLA
 BC070467 mitogen activated protein kinase kinase 7, mRNA (cDNA clone MGC:96654 IMAGE:30615302), complete cds [BC070467] KLA .77 .79 .88 .77 .97 .96 1.27
ATP 1.11 1.26 .93 1.19 1.13 1.45 1.16
KLA/ATP .89 .88 .59 .89 .86 1.32 1.28
Map2k7
KLA  ATP  ATP+KLA
 NM_001042557 mitogen-activated protein kinase kinase 7 (Map2k7), transcript variant 1, mRNA [NM_001042557] KLA .96 .95 1.02 .96 .95 1.09 1.19
ATP 1.02 1.07 .88 .97 .93 1.10 1.17
KLA/ATP 1.01 .99 .80 .87 .76 1.21 1.16
Map3k1
KLA  ATP  ATP+KLA
 NM_011945 mitogen-activated protein kinase kinase kinase 1 (Map3k1), mRNA [NM_011945] KLA .30 .25 .37 .56 .68 1.07 .85
ATP .88 .86 1.26 1.04 1.07 .77 .78
KLA/ATP .28 .24 .59 .99 1.49 .97 1.24
Map3k11
KLA  ATP  ATP+KLA
 NM_022012 mitogen-activated protein kinase kinase kinase 11 (Map3k11), mRNA [NM_022012] KLA .85 .93 .96 1.04 1.39 1.23 1.05
ATP 1.06 1.10 .62 .85 .81 1.21 1.03
KLA/ATP 1.05 .90 .51 .86 .93 1.31 1.80
Map3k12
KLA  ATP  ATP+KLA
 NM_009582 mitogen-activated protein kinase kinase kinase 12 (Map3k12), mRNA [NM_009582] KLA .46 .44 .49 .55 .61 .70 .66
ATP .93 .90 .93 .81 .54 .60 1.29
KLA/ATP .45 .44 .50 .56 .61 .62 .85
Map3k12
KLA  ATP  ATP+KLA
 U09541 CD1 protein kinase mRNA, partial cds. [U09541] KLA .73 .66 .64 .72 .68 .73 .82
ATP .97 .98 .83 .86 .62 .68 1.32
KLA/ATP .70 .64 .67 .69 .63 .69 .94
Map3k13
KLA  ATP  ATP+KLA
 NM_172821 mitogen-activated protein kinase kinase kinase 13 (Map3k13), mRNA [NM_172821] KLA .96 .97 .98 1.02 1.02 1.05 1.02
ATP 1.03 1.02 .89 .93 1.00 1.05 .92
KLA/ATP 1.02 .97 .99 .91 .95 .98 1.08
Map3k14
KLA  ATP  ATP+KLA
 NM_016896 mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] KLA .32 .30 .40 .52 1.08 1.14 .94
ATP 1.18 1.24 1.13 .85 .82 .84 .99
KLA/ATP .33 .30 .34 .50 1.02 .84 1.43
Map3k2
KLA  ATP  ATP+KLA
 NM_011946 mitogen-activated protein kinase kinase kinase 2 (Map3k2), mRNA [NM_011946] KLA .80 .79 .74 .79 .93 1.00 1.09
ATP .99 .97 1.05 1.13 1.79 1.27 1.14
KLA/ATP .81 .76 .77 .84 1.39 1.29 1.26
Map3k3
KLA  ATP  ATP+KLA
 NM_011947 mitogen-activated protein kinase kinase kinase 3 (Map3k3), mRNA [NM_011947] KLA .60 .63 .60 .58 .81 1.03 1.26
ATP .97 .91 .55 .58 .71 .81 .99
KLA/ATP .68 .57 .42 .53 .61 .85 1.23
Map3k4
KLA  ATP  ATP+KLA
 AK035823 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630008E23 product:mitogen activated protein kinase kinase kinase 4, full insert sequence. [AK035823] KLA 1.04 .92 1.04 .92 .96 .98 1.01
ATP 1.00 .95 .99 .99 1.01 .95 1.01
KLA/ATP .99 1.06 .94 1.02 1.03 1.00 .97
Map3k4
KLA  ATP  ATP+KLA
 NM_011948 mitogen-activated protein kinase kinase kinase 4 (Map3k4), mRNA [NM_011948] KLA .56 .57 .58 .66 .81 .94 .99
ATP .97 .93 1.13 .98 .65 .60 .95
KLA/ATP .54 .54 .64 .61 .69 .70 .91
Map3k5
KLA  ATP  ATP+KLA
 NM_008580 mitogen-activated protein kinase kinase kinase 5 (Map3k5), mRNA [NM_008580] KLA 1.85 1.97 1.17 .82 .57 .47 .49
ATP 1.06 1.05 .94 1.22 1.55 .91 .32
KLA/ATP 2.00 1.82 .95 .91 .60 .34 .28
Map3k6
KLA  ATP  ATP+KLA
 NM_016693 mitogen-activated protein kinase kinase kinase 6 (Map3k6), mRNA [NM_016693] KLA 1.43 1.27 .88 .74 .97 1.03 1.16
ATP .99 .95 1.11 1.07 1.52 1.92 .71
KLA/ATP 1.44 1.28 1.17 .98 1.00 .74 .51
Map3k7
KLA  ATP  ATP+KLA
 NM_172688 mitogen-activated protein kinase kinase kinase 7 (Map3k7), mRNA [NM_172688] KLA 1.48 1.49 1.51 1.24 1.21 1.19 1.61
ATP 1.10 1.16 1.03 1.03 1.12 1.61 1.61
KLA/ATP 1.43 1.56 1.05 1.15 .85 1.48 1.76
Map3k7ip
1
KLA  ATP  ATP+KLA
 NM_025609 mitogen-activated protein kinase kinase kinase 7 interacting protein 1 (Map3k7ip1), mRNA [NM_025609] KLA .32 .30 .35 .56 .67 .82 .76
ATP .95 .81 .80 .42 .35 .40 .80
KLA/ATP .33 .30 .37 .20 .45 .62 .65
Map3k7ip
2
KLA  ATP  ATP+KLA
 AK086230 15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930015C19 product:inferred: Mus musculus, Similar to TAK1-binding protein 2; KIAA0733 protein, clone MGC:8010 IMAGE:3586132, mRNA, complete cds, full insert sequence. [A KLA 1.14 1.02 1.07 1.03 1.13 1.02 .96
ATP 1.00 .88 .92 .90 1.06 .96 .94
KLA/ATP 1.05 1.00 .90 .98 1.02 .97 .97
Map3k7ip
2
KLA  ATP  ATP+KLA
 NM_138667 mitogen-activated protein kinase kinase kinase 7 interacting protein 2 (Map3k7ip2), mRNA [NM_138667] KLA 3.43 3.22 3.19 2.41 2.13 1.51 1.10
ATP 1.08 1.08 .86 .81 1.30 1.32 1.02
KLA/ATP 3.34 3.66 3.00 2.58 1.80 1.52 1.61
Map3k8
KLA  ATP  ATP+KLA
 D13759 cot mRNA for proto-oncogene protein, complete cds. [D13759] KLA 11.38 11.64 13.24 13.31 10.92 5.26 3.31
ATP 1.36 1.09 1.75 6.27 10.51 3.58 1.60
KLA/ATP 12.58 11.57 8.93 14.10 13.92 4.98 4.09
Map4k1
KLA  ATP  ATP+KLA
 NM_008279 mitogen-activated protein kinase kinase kinase kinase 1 (Map4k1), mRNA [NM_008279] KLA .55 .56 .51 .47 .41 .37 .40
ATP .92 .84 1.18 1.05 .74 .36 .54
KLA/ATP .55 .54 .63 .57 .54 .34 .30
Map4k2
KLA  ATP  ATP+KLA
 AK154164 NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630005M21 product:mitogen activated protein kinase kinase kinase kinase 2, full insert sequence [AK154164] KLA .82 .77 .80 .78 .78 .75 .72
ATP 1.05 1.14 .99 .93 .68 .67 .55
KLA/ATP .76 .81 .74 .74 .72 .69 .53
Map4k2
KLA  ATP  ATP+KLA
 NM_009006 mitogen-activated protein kinase kinase kinase kinase 2 (Map4k2), mRNA [NM_009006] KLA .83 .84 .93 .88 .89 .88 .96
ATP 1.18 1.23 1.06 1.34 .87 .92 1.01
KLA/ATP 1.00 .90 .79 1.09 .84 .78 1.04
Map4k3
KLA  ATP  ATP+KLA
 NM_001081357 mitogen-activated protein kinase kinase kinase kinase 3 (Map4k3), mRNA [NM_001081357] KLA .45 .46 .67 1.09 1.60 2.12 1.48
ATP 1.02 1.13 1.00 1.05 .64 .52 1.88
KLA/ATP .48 .43 .53 .79 .61 .58 2.44
Map4k4
KLA  ATP  ATP+KLA
 NM_008696 mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4), mRNA [NM_008696] KLA 1.03 .91 .82 .89 .90 1.09 .91
ATP 1.01 .90 1.01 1.11 1.53 1.84 1.11
KLA/ATP .97 .85 .84 .83 1.16 1.34 1.41
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
 AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
 NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk11
KLA  ATP  ATP+KLA
 NM_011161 mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] KLA 1.28 1.30 1.41 1.46 1.58 1.29 .98
ATP .96 .95 .89 .82 .79 1.09 .85
KLA/ATP 1.44 1.42 1.32 1.23 1.23 .74 .66
Mapk12
KLA  ATP  ATP+KLA
 NM_013871 mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] KLA .94 .86 .87 .81 .77 .68 .49
ATP .97 .83 .92 .90 .86 .90 .51
KLA/ATP .91 .89 .88 .85 1.12 1.14 .53
Mapk13
KLA  ATP  ATP+KLA
 NM_011950 mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] KLA 1.22 1.21 1.35 1.26 1.24 1.13 1.01
ATP 1.08 1.00 1.20 1.20 1.13 1.22 1.39
KLA/ATP 1.22 1.27 1.30 1.30 1.21 1.11 1.47
Mapk14
KLA  ATP  ATP+KLA
 NM_011951 mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] KLA .70 .70 .62 .54 .67 .88 1.11
ATP 1.03 .98 .87 .69 .48 .78 .66
KLA/ATP .74 .68 .52 .46 .38 .45 .62
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk7
KLA  ATP  ATP+KLA
 NM_011841 mitogen-activated protein kinase 7 (Mapk7), mRNA [NM_011841] KLA .46 .43 .53 .80 1.03 1.38 1.55
ATP .96 .80 .84 .62 1.76 2.01 1.67
KLA/ATP .39 .40 .47 .50 2.55 1.93 2.48
Mapk8
KLA  ATP  ATP+KLA
 AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
 AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
 NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk8ip1
KLA  ATP  ATP+KLA
 AK053819 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130310D04 product:unclassifiable, full insert sequence. [AK053819] KLA 1.02 .96 .99 1.00 1.00 .96 .96
ATP 1.00 .99 1.01 .99 1.08 .99 1.00
KLA/ATP .95 1.02 .99 1.03 1.26 1.06 1.02
Mapk8ip1
KLA  ATP  ATP+KLA
 NM_011162 mitogen-activated protein kinase 8 interacting protein 1 (Mapk8ip1), mRNA [NM_011162] KLA .95 .95 .90 .81 .87 .88 .93
ATP 1.05 1.11 1.06 .98 .94 .98 .98
KLA/ATP .97 .84 .91 .88 .94 .98 .84
Mapk8ip2
KLA  ATP  ATP+KLA
 NM_021921 mitogen-activated protein kinase 8 interacting protein 2 (Mapk8ip2), mRNA [NM_021921] KLA .94 1.03 1.00 .99 1.06 1.05 .98
ATP .97 1.09 1.01 1.02 .96 1.04 1.09
KLA/ATP .98 .95 1.01 1.16 1.07 1.01 1.03
Mapk8ip3
KLA  ATP  ATP+KLA
 AK035619 adult male urinary bladder cDNA, RIKEN full-length enriched library, clone:9530077J01 product:mitogen-activated protein kinase 8 interacting protein 3, full insert sequence. [AK035619] KLA .81 .81 .78 .77 .83 .83 1.03
ATP .96 .93 .86 .80 .72 .73 1.36
KLA/ATP .74 .79 .81 .74 .71 .76 .87
Mapk8ip3
KLA  ATP  ATP+KLA
 NM_013931 mitogen-activated protein kinase 8 interacting protein 3 (Mapk8ip3), mRNA [NM_013931] KLA .84 .81 .98 1.24 1.63 1.45 1.08
ATP 1.09 .98 1.14 .69 1.46 1.58 1.32
KLA/ATP .89 .78 .99 .55 1.55 1.39 1.80
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mapkapk2
KLA  ATP  ATP+KLA
 NM_008551 MAP kinase-activated protein kinase 2 (Mapkapk2), mRNA [NM_008551] KLA 5.20 5.49 5.81 5.35 5.43 2.98 2.19
ATP 1.04 1.12 1.00 1.50 1.88 2.43 1.01
KLA/ATP 5.63 5.95 4.08 4.71 3.33 2.24 2.50
Mapkapk3
KLA  ATP  ATP+KLA
 NM_178907 mitogen-activated protein kinase-activated protein kinase 3 (Mapkapk3), mRNA [NM_178907] KLA 1.39 1.20 .92 .63 .69 .77 1.17
ATP 1.08 .93 .62 .89 2.84 2.80 1.08
KLA/ATP 1.51 1.23 .77 .81 1.96 2.29 1.74
Mapkapk5
KLA  ATP  ATP+KLA
 NM_010765 MAP kinase-activated protein kinase 5 (Mapkapk5), mRNA [NM_010765] KLA 1.07 1.10 1.11 1.07 1.16 1.24 1.40
ATP .97 1.00 .99 .99 1.05 1.18 1.12
KLA/ATP 1.05 1.10 1.04 .87 .92 1.06 1.20
Mapt
KLA  ATP  ATP+KLA
 NM_001038609 microtubule-associated protein tau (Mapt), transcript variant 1, mRNA [NM_001038609] KLA .96 1.10 1.00 .97 .92 1.01 1.00
ATP .96 1.05 1.10 .94 1.06 1.03 .93
KLA/ATP .99 1.07 1.06 .94 1.18 1.05 .98
Max
KLA  ATP  ATP+KLA
 NM_008558 Max protein (Max), mRNA [NM_008558] KLA 3.40 3.25 4.09 4.53 3.19 2.71 1.19
ATP 1.17 1.09 1.13 .86 1.24 1.40 1.09
KLA/ATP 3.14 3.36 5.49 3.83 4.35 2.96 1.67
Mef2c
KLA  ATP  ATP+KLA
 AK044643 adult retina cDNA, RIKEN full-length enriched library, clone:A930029G05 product:unclassifiable, full insert sequence. [AK044643] KLA .97 .95 .99 .99 .96 .92 .97
ATP 1.03 1.09 1.08 .96 1.03 .85 .90
KLA/ATP .92 .99 .94 .83 .90 .93 .91
Mef2c
KLA  ATP  ATP+KLA
 NM_025282 myocyte enhancer factor 2C (Mef2c), mRNA [NM_025282] KLA .36 .35 .34 .44 .25 .31 .24
ATP 1.10 .84 .84 .97 .39 .19 .41
KLA/ATP .35 .32 .41 .44 .33 .19 .18
Mknk1
KLA  ATP  ATP+KLA
 NM_021461 MAP kinase-interacting serine/threonine kinase 1 (Mknk1), mRNA [NM_021461] KLA .78 .81 .88 .86 .98 1.12 .93
ATP 1.04 1.03 1.03 1.07 .70 .67 1.09
KLA/ATP .83 .83 .81 .84 .66 .88 1.12
Mknk2
KLA  ATP  ATP+KLA
 NM_021462 MAP kinase-interacting serine/threonine kinase 2 (Mknk2), mRNA [NM_021462] KLA .19 .18 .16 .15 .20 .50 .62
ATP .89 .86 1.35 2.05 1.76 1.52 1.29
KLA/ATP .19 .17 .32 .99 1.61 2.33 1.97
Mm.13849
KLA  ATP  ATP+KLA
 158937311 Unknown KLA 1.71 1.69 1.64 1.89 1.78 1.97 1.25
ATP 1.00 1.23 5.40 7.14 6.79 7.89 4.71
KLA/ATP 1.73 1.75 5.04 7.35 8.18 7.92 6.07
Mm.15898
1
KLA  ATP  ATP+KLA
 142388182 Unknown KLA .25 .22 .31 .50 .85 1.11 .83
ATP 1.02 .94 1.31 .76 .73 .96 .92
KLA/ATP .24 .22 .34 .38 1.16 .96 1.23
Mm.1741
KLA  ATP  ATP+KLA
 31982052 Unknown KLA 4.05 3.90 3.12 3.55 4.00 3.37 2.25
ATP 1.01 1.01 1.44 2.36 3.07 3.54 1.27
KLA/ATP 4.19 3.74 4.02 4.02 3.13 2.82 3.33
Mm.20374
7
KLA  ATP  ATP+KLA
 146149233 Unknown KLA .34 .30 .28 .41 .80 1.31 1.29
ATP .93 .83 .82 .76 .43 .46 .88
KLA/ATP .30 .28 .27 .27 .27 .51 1.11
Mm.21499
4
KLA  ATP  ATP+KLA
 148540002 Unknown KLA 1.04 1.08 1.14 1.05 1.07 1.18 1.23
ATP 1.02 .99 1.08 1.05 1.00 1.01 1.01
KLA/ATP 1.02 1.11 1.10 .99 1.03 1.10 1.11
Mm.23904
1
KLA  ATP  ATP+KLA
 145301574 Unknown KLA 4.48 4.00 7.76 10.91 8.92 5.66 4.86
ATP 4.23 6.26 25.25 43.30 8.11 8.22 2.78
KLA/ATP 6.59 8.15 19.54 43.73 11.92 15.37 15.81
Mm.27558
4
KLA  ATP  ATP+KLA
 142385539 Unknown KLA .18 .17 .27 .47 .60 .43 .37
ATP 1.13 1.12 1.06 1.06 1.18 .46 .89
KLA/ATP .16 .16 .24 .33 .42 .35 .31
Mm.27970
KLA  ATP  ATP+KLA
 13994135 Unknown KLA 1.06 1.11 1.16 1.07 1.11 1.08 .95
ATP 1.02 1.09 1.05 1.05 .94 1.16 1.32
KLA/ATP 1.10 1.19 1.11 1.04 1.08 1.02 1.33
Mm.28964
6
KLA  ATP  ATP+KLA
 146198766 Unknown KLA .61 .59 .55 .58 .52 .72 .60
ATP 1.13 1.14 .82 .79 .59 .39 .61
KLA/ATP .66 .61 .58 .71 .52 .38 .50
Mm.29105
8
KLA  ATP  ATP+KLA
 157057193 Unknown KLA 1.02 .94 .97 .97 1.03 1.00 1.00
ATP 1.03 1.01 1.10 .95 .95 1.00 1.03
KLA/ATP .97 .93 1.06 1.02 1.04 .94 1.02
Mm.32574
6
KLA  ATP  ATP+KLA
 118130017 Unknown KLA .71 .67 .65 .62 .73 .74 .83
ATP 1.03 .83 .89 .79 .93 1.17 .78
KLA/ATP .77 .62 .61 .55 .79 1.11 .78
Mm.33050
7
KLA  ATP  ATP+KLA
 67906182 Unknown KLA .94 .98 .99 1.03 1.05 1.07 .98
ATP .95 1.02 .97 .98 .99 1.05 1.02
KLA/ATP 1.02 1.05 1.01 1.03 .99 .98 .97
Mm.33138
9
KLA  ATP  ATP+KLA
 158508469 Unknown KLA .80 .79 .81 .82 .72 .64 .50
ATP .95 .85 .56 .48 .30 .33 .46
KLA/ATP .71 .64 .50 .41 .33 .32 .42
Mm.33981
2
KLA  ATP  ATP+KLA
 6679780 Unknown KLA 1.10 1.14 1.09 1.05 1.05 1.08 1.01
ATP .95 1.06 2.35 11.15 2.46 1.50 1.03
KLA/ATP 1.02 1.05 2.05 8.78 2.65 1.76 1.02
Mm.35799
0
KLA  ATP  ATP+KLA
 21687185 Unknown KLA 1.18 1.20 1.19 1.23 1.18 1.19 1.10
ATP .97 1.07 1.11 1.19 1.01 1.15 .98
KLA/ATP 1.06 1.29 1.19 1.29 1.19 1.10 1.10
Mm.41274
5
KLA  ATP  ATP+KLA
 110681696 Unknown KLA .97 1.07 1.11 1.07 1.38 1.63 1.35
ATP 1.06 1.09 1.05 1.29 1.04 .50 .56
KLA/ATP 1.11 1.12 1.04 1.11 .92 .83 .74
Mm.41292
2
KLA  ATP  ATP+KLA
 145966829 Unknown KLA 3.65 3.76 3.75 3.79 3.42 1.75 1.10
ATP 1.11 1.17 1.04 .90 1.37 2.90 1.00
KLA/ATP 3.31 3.97 3.38 3.84 3.04 3.31 2.09
Mm.43824
7
KLA  ATP  ATP+KLA
 118130208 Unknown KLA 1.43 1.43 1.34 1.56 1.23 1.37 1.20
ATP .98 1.05 1.20 1.46 1.21 1.28 1.08
KLA/ATP 1.37 1.34 1.71 1.70 1.41 1.42 1.32
Mm.44077
3
KLA  ATP  ATP+KLA
 124517717 Unknown KLA .69 .69 .71 .76 .71 .73 .58
ATP .93 .96 1.01 .85 .73 .76 .57
KLA/ATP .60 .65 .75 .80 .76 .66 .55
Mm.4424
KLA  ATP  ATP+KLA
 110225367 Unknown KLA .99 .93 1.01 1.02 1.00 .92 1.00
ATP .98 1.03 3.11 1.13 1.19 1.03 1.11
KLA/ATP .95 .97 .97 .96 .93 1.01 .99
Mm.44591
2
KLA  ATP  ATP+KLA
 9506452 Unknown KLA .98 .99 1.00 1.07 .99 .98 1.07
ATP 1.02 1.05 .94 .96 1.01 1.00 .94
KLA/ATP 1.01 1.08 1.04 .92 .92 1.00 1.03
Mm.44981
2
KLA  ATP  ATP+KLA
 84370346 Unknown KLA 1.01 .97 .97 .96 .96 1.00 .94
ATP .96 .95 1.01 .93 .95 1.01 1.02
KLA/ATP .93 .92 .94 .91 .97 .98 .98
Mm.45044
KLA  ATP  ATP+KLA
 133892959 Unknown KLA .51 .47 .52 .83 1.25 1.16 .60
ATP 1.09 .78 .80 .63 .83 .89 .41
KLA/ATP .49 .42 .44 .39 .89 1.04 .41
Mm.45825
9
KLA  ATP  ATP+KLA
 116292181 Unknown KLA .84 .86 .91 .85 .98 .98 1.00
ATP 1.05 1.06 .94 .95 1.00 .89 .89
KLA/ATP .92 .84 .87 .93 .91 .92 .82
Mm.46002
4
KLA  ATP  ATP+KLA
 38348245 Unknown KLA 1.22 1.25 1.25 1.19 1.22 1.47 1.14
ATP 1.03 .94 1.01 1.01 2.67 2.31 1.37
KLA/ATP 1.35 1.19 1.27 1.22 1.99 1.83 1.45
Mm.46359
0
KLA  ATP  ATP+KLA
 21687181 Unknown KLA .76 .80 .87 .99 .94 1.02 .98
ATP .90 .94 1.06 .97 .83 .93 .85
KLA/ATP .79 .91 .98 1.01 .97 .84 .78
Mm.5055
KLA  ATP  ATP+KLA
 145966820 Unknown KLA 1.04 .96 1.04 .97 1.00 1.00 .97
ATP .95 .97 .96 .95 .97 .97 .98
KLA/ATP .88 1.04 1.07 1.02 .97 .98 .96
Mm.56965
KLA  ATP  ATP+KLA
 6679704 Unknown KLA .96 1.05 1.06 1.01 1.05 .99 .98
ATP .95 .99 .93 1.05 .97 .96 1.02
KLA/ATP .95 1.01 1.03 1.02 .98 .98 .98
Mm.80682
KLA  ATP  ATP+KLA
 94369627 Unknown KLA .96 1.00 .97 .97 1.07 1.05 .99
ATP .97 1.02 .98 1.01 1.01 1.06 .96
KLA/ATP 1.00 .93 1.02 1.08 .98 .95 .97
Mm.87663
KLA  ATP  ATP+KLA
 142370454 Unknown KLA 1.04 1.01 1.01 1.10 .95 1.04 .95
ATP .96 1.01 .96 .98 .94 1.05 1.12
KLA/ATP .98 .97 1.12 1.03 1.06 .94 1.02
Mos
KLA  ATP  ATP+KLA
 NM_020021 Moloney sarcoma oncogene (Mos), mRNA [NM_020021] KLA 1.14 1.04 1.00 .98 1.09 .94 .98
ATP 1.00 1.01 1.03 1.05 .92 1.04 1.12
KLA/ATP .97 .96 1.04 1.03 .95 .99 1.03
Mras
KLA  ATP  ATP+KLA
 NM_008624 muscle and microspikes RAS (Mras), mRNA [NM_008624] KLA .77 .76 .75 .84 .92 .87 1.35
ATP 1.02 1.00 1.11 1.14 .87 .79 .80
KLA/ATP .77 .77 .86 .78 .69 .63 .61
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Nf1
KLA  ATP  ATP+KLA
 NM_010897 neurofibromatosis 1 (Nf1), mRNA [NM_010897] KLA .96 1.05 .95 .91 1.05 1.02 1.04
ATP .96 1.04 .97 .99 .82 .86 1.31
KLA/ATP 1.05 1.03 .88 .93 .72 .79 1.28
Nfatc2
KLA  ATP  ATP+KLA
 AK081853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] KLA .56 .52 .59 .61 .78 .78 .66
ATP 1.19 1.27 .67 .65 .62 .53 .79
KLA/ATP .52 .49 .71 .57 .65 .52 .53
Nfatc2
KLA  ATP  ATP+KLA
 NM_001037177 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] KLA .84 .79 .74 .82 .89 .98 .80
ATP 1.06 1.13 1.01 .87 .86 .83 1.10
KLA/ATP .76 .72 .89 .84 .84 .81 .84
Nfatc2
KLA  ATP  ATP+KLA
 NM_010899 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] KLA .90 .91 .86 .91 .86 1.07 1.00
ATP 1.08 1.11 1.45 1.04 .88 .85 1.18
KLA/ATP .85 .89 .92 .89 .93 .84 1.13
Nfatc4
KLA  ATP  ATP+KLA
 AK014164 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] KLA .90 .92 .91 1.00 .99 .98 .95
ATP .90 1.03 .96 .98 .95 .97 1.00
KLA/ATP .95 .87 1.00 .98 .96 .96 .92
Nfatc4
KLA  ATP  ATP+KLA
 NM_023699 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] KLA 1.28 1.38 1.44 1.58 1.40 1.41 1.46
ATP 1.03 1.06 1.23 1.24 1.32 1.40 1.41
KLA/ATP 1.30 1.38 1.47 1.28 1.38 1.40 1.63
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkb2
KLA  ATP  ATP+KLA
 NM_019408 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 (Nfkb2), mRNA [NM_019408] KLA 7.31 7.92 7.95 6.42 6.41 4.42 2.81
ATP .99 .98 .72 1.48 2.80 5.31 1.44
KLA/ATP 8.25 7.93 6.51 7.68 5.08 4.38 4.86
Ngf
KLA  ATP  ATP+KLA
 NM_013609 nerve growth factor (Ngf), transcript variant A, mRNA [NM_013609] KLA .99 .98 .97 .99 .97 1.10 1.05
ATP .94 1.03 .99 1.00 .93 1.05 1.01
KLA/ATP .94 1.01 .99 .98 .98 1.11 1.02
Nlk
KLA  ATP  ATP+KLA
 NM_008702 nemo like kinase (Nlk), mRNA [NM_008702] KLA .71 .70 .64 .71 .78 .95 .94
ATP .91 .89 .95 .70 .45 .64 1.05
KLA/ATP .61 .66 .84 .54 .53 .58 .79
Nr4a1
KLA  ATP  ATP+KLA
 NM_010444 nuclear receptor subfamily 4, group A, member 1 (Nr4a1), mRNA [NM_010444] KLA .44 .45 .47 .82 .71 .50 .55
ATP 11.54 20.34 46.57 49.45 32.16 7.11 .84
KLA/ATP 4.55 17.35 51.68 56.03 42.95 13.43 2.21
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Ntf3
KLA  ATP  ATP+KLA
 NM_008742 neurotrophin 3 (Ntf3), mRNA [NM_008742] KLA 1.08 .93 1.06 1.02 1.03 1.01 .96
ATP 1.00 1.03 .96 .94 .96 1.01 1.02
KLA/ATP .95 1.00 .98 1.01 .96 .94 1.02
Ntf5
KLA  ATP  ATP+KLA
 NM_198190 neurotrophin 5 (Ntf5), mRNA [NM_198190] KLA 1.07 1.02 .97 1.03 1.06 .98 1.03
ATP 1.00 1.05 .97 .99 1.01 1.02 1.05
KLA/ATP .98 1.00 1.10 1.02 .95 .96 1.06
Ntrk1
KLA  ATP  ATP+KLA
 NM_001033124 neurotrophic tyrosine kinase, receptor, type 1 (Ntrk1), mRNA [NM_001033124] KLA .95 .96 1.03 1.03 .95 1.01 1.02
ATP 1.04 .98 .98 1.07 .99 1.01 1.02
KLA/ATP .97 1.03 1.10 1.02 1.05 1.00 .97
Ntrk2
KLA  ATP  ATP+KLA
 AK018789 adult male cerebellum cDNA, RIKEN full-length enriched library, clone:1500040I13 product:neurotrophic tyrosine kinase, receptor, type 2, full insert sequence. [AK018789] KLA 1.02 .94 1.05 1.03 1.03 1.03 1.04
ATP .99 1.01 1.09 .95 1.02 .99 1.04
KLA/ATP 1.02 .96 1.00 1.04 1.13 .99 1.03
Ntrk2
KLA  ATP  ATP+KLA
 NM_001025074 neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2), transcript variant 1, mRNA [NM_001025074] KLA .99 .99 1.02 1.02 1.02 1.00 1.03
ATP .99 .99 .99 .99 1.00 1.01 1.03
KLA/ATP .97 1.00 1.01 1.00 .99 .98 1.00
Ntrk2
KLA  ATP  ATP+KLA
 NM_008745 neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2), transcript variant 2, mRNA [NM_008745] KLA .99 1.00 .99 1.00 .99 1.00 1.02
ATP 1.01 1.00 1.01 .97 1.01 1.01 .99
KLA/ATP .99 1.01 .99 1.01 .99 .99 1.01
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pdgfrb
KLA  ATP  ATP+KLA
 NM_008809 platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] KLA 4.85 5.49 4.56 3.94 3.71 2.05 1.51
ATP .99 1.00 1.11 1.27 1.02 1.83 1.23
KLA/ATP 5.09 5.86 4.30 2.51 1.74 1.84 3.23
Pla2g4a
KLA  ATP  ATP+KLA
 NM_008869 phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] KLA 3.93 4.49 4.86 6.40 6.44 3.10 1.68
ATP 1.13 1.36 1.27 1.30 1.02 5.37 1.47
KLA/ATP 3.64 4.45 4.76 7.11 2.96 4.08 2.60
Pla2g4b
KLA  ATP  ATP+KLA
 NM_145378 phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] KLA 1.09 1.18 .95 1.01 .97 .97 .77
ATP 1.05 1.14 1.28 .94 .88 1.18 .70
KLA/ATP 1.23 1.43 1.21 1.02 1.15 1.16 .78
Pla2g4c
KLA  ATP  ATP+KLA
 AK145339 1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] KLA 1.09 1.21 1.33 1.17 1.26 1.30 1.05
ATP .97 1.06 1.00 .98 .98 .98 1.05
KLA/ATP 1.19 1.16 1.18 1.13 1.04 1.02 1.06
Pla2g4c
KLA  ATP  ATP+KLA
 NM_001004762 phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] KLA .93 1.00 .94 .93 .94 .94 .96
ATP .98 .96 1.13 .97 .99 .89 .96
KLA/ATP 1.01 1.01 1.07 1.01 .94 1.01 .92
Pla2g4e
KLA  ATP  ATP+KLA
 AK049063 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] KLA 1.03 1.09 1.01 1.01 1.06 .94 1.05
ATP 1.03 1.00 1.06 1.01 .96 1.05 1.05
KLA/ATP .98 1.00 1.01 .98 1.03 .95 1.01
Pla2g4e
KLA  ATP  ATP+KLA
 NM_177845 phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] KLA .97 .95 1.01 .97 1.02 1.03 1.05
ATP .98 .99 1.00 1.10 .98 1.00 1.02
KLA/ATP 1.05 .93 .96 1.03 1.08 1.05 .99
Pla2g4f
KLA  ATP  ATP+KLA
 NM_001024145 phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] KLA 1.08 .99 1.04 1.02 1.04 .98 1.01
ATP .99 1.04 .99 1.03 1.12 1.01 1.25
KLA/ATP .97 1.04 1.10 1.06 1.04 1.03 1.03
Ppm1a
KLA  ATP  ATP+KLA
 AF369981 PP alpha 2 mRNA, complete cds [AF369981] KLA 1.37 1.28 1.19 1.18 1.04 .95 1.26
ATP 1.06 1.04 1.25 .86 1.05 1.19 1.13
KLA/ATP 1.50 1.39 1.29 .90 .94 .77 .83
Ppm1a
KLA  ATP  ATP+KLA
 NM_008910 protein phosphatase 1A, magnesium dependent, alpha isoform (Ppm1a), mRNA [NM_008910] KLA 1.12 1.12 1.11 .92 .96 .91 1.15
ATP 1.04 1.07 .94 .97 1.28 1.56 1.07
KLA/ATP 1.09 1.14 .95 1.02 1.17 1.41 1.34
Ppm1b
KLA  ATP  ATP+KLA
 BC090963 protein phosphatase 1B, magnesium dependent, beta isoform, mRNA (cDNA clone MGC:106489 IMAGE:30632168), complete cds. [BC090963] KLA 1.44 1.37 1.24 1.09 1.02 .84 1.36
ATP 1.27 1.33 1.25 .97 .77 .47 .58
KLA/ATP 1.42 1.59 1.60 1.20 .75 .30 .43
Ppm1b
KLA  ATP  ATP+KLA
 NM_011151 protein phosphatase 1B, magnesium dependent, beta isoform (Ppm1b), mRNA [NM_011151] KLA 1.91 1.87 1.82 1.60 1.43 1.18 1.21
ATP .98 .99 .96 1.03 1.28 1.55 .87
KLA/ATP 1.79 1.98 1.86 1.73 1.68 1.52 1.05
Ppp3ca
KLA  ATP  ATP+KLA
 NM_008913 protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] KLA .76 .85 .81 .85 .73 .70 .52
ATP .96 .78 .55 .46 .31 .33 .48
KLA/ATP .74 .64 .52 .42 .37 .36 .45
Ppp3cb
KLA  ATP  ATP+KLA
 AK135203 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] KLA 1.74 1.57 1.91 1.59 1.47 1.26 1.40
ATP 1.17 1.03 1.30 1.00 .81 .62 1.37
KLA/ATP 1.68 1.70 1.91 1.37 1.09 .47 1.13
Ppp3cb
KLA  ATP  ATP+KLA
 AK171904 activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] KLA 1.29 1.29 1.21 1.15 1.22 1.13 1.28
ATP .90 .86 .80 .98 .94 .73 .92
KLA/ATP 1.06 1.03 .77 1.04 .92 .68 .90
Ppp3cb
KLA  ATP  ATP+KLA
 NM_008914 protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] KLA 1.21 1.29 1.38 1.24 1.29 1.08 1.23
ATP 1.15 1.31 1.09 1.29 .86 .60 .64
KLA/ATP 1.33 1.40 1.04 1.28 .79 .58 .73
Ppp3cc
KLA  ATP  ATP+KLA
 AK037563 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] KLA 1.27 1.18 1.21 1.15 1.01 .92 1.36
ATP .96 1.09 1.10 1.03 .85 1.06 1.47
KLA/ATP 1.17 1.24 1.07 1.13 .91 .88 1.36
Ppp3cc
KLA  ATP  ATP+KLA
 NM_008915 protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] KLA 1.64 1.81 1.79 1.35 .90 .70 1.31
ATP .90 .90 1.13 .93 .86 1.40 1.60
KLA/ATP 1.45 1.62 1.74 1.47 1.04 1.01 1.31
Ppp3r1
KLA  ATP  ATP+KLA
 NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] KLA 1.02 1.17 .93 1.27 1.15 1.30 1.30
ATP .97 .95 .77 .91 .99 1.18 1.10
KLA/ATP 1.12 1.04 .88 1.00 1.10 1.10 1.07
Ppp3r2
KLA  ATP  ATP+KLA
 NM_001004025 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] KLA 1.03 1.05 1.06 1.08 1.12 1.05 1.04
ATP 1.00 1.02 1.04 1.04 .99 .99 1.01
KLA/ATP 1.04 1.12 1.03 1.09 1.00 .99 1.00
Ppp5c
KLA  ATP  ATP+KLA
 NM_011155 protein phosphatase 5, catalytic subunit (Ppp5c), mRNA [NM_011155] KLA .85 .80 .89 .80 .90 1.05 1.20
ATP 1.00 1.07 .99 1.15 1.16 .97 .88
KLA/ATP .86 .86 .78 .91 .93 .97 .78
Prkaca
KLA  ATP  ATP+KLA
 NM_008854 protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] KLA .71 .74 .72 .70 .72 .84 .85
ATP 1.05 .98 .89 .92 .76 .60 1.02
KLA/ATP .79 .74 .55 .65 .60 .65 .93
Prkacb
KLA  ATP  ATP+KLA
 NM_011100 protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] KLA .69 .70 .66 .58 .51 .55 .59
ATP 1.02 1.19 .97 1.01 .69 .38 .56
KLA/ATP .72 .73 .57 .62 .47 .41 .45
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Prkx
KLA  ATP  ATP+KLA
 NM_016979 protein kinase, X-linked (Prkx), mRNA [NM_016979] KLA 3.61 3.79 4.67 4.66 4.85 4.19 1.43
ATP .98 .90 .63 .61 1.12 1.90 1.29
KLA/ATP 3.56 3.36 2.62 2.06 2.26 2.87 2.31
Ptpn5
KLA  ATP  ATP+KLA
 NM_013643 protein tyrosine phosphatase, non-receptor type 5 (Ptpn5), mRNA [NM_013643] KLA 1.16 1.20 1.25 1.15 1.23 1.13 1.16
ATP .96 1.13 1.54 2.10 1.88 1.28 1.02
KLA/ATP 1.12 1.12 2.12 1.93 2.07 1.59 1.30
Ptpn7
KLA  ATP  ATP+KLA
 NM_177081 protein tyrosine phosphatase, non-receptor type 7 (Ptpn7), mRNA [NM_177081] KLA .31 .31 .35 .43 .68 .86 .77
ATP .97 1.06 .86 .82 .50 .68 .92
KLA/ATP .33 .30 .31 .34 .34 .51 .79
Ptprr
KLA  ATP  ATP+KLA
 AK051719 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130067J21 product:protein tyrosine phosphatase, receptor type, R, full insert sequence. [AK051719] KLA .99 .98 .95 1.00 .99 .95 .95
ATP 1.03 .98 .97 1.03 .92 1.07 1.01
KLA/ATP .98 1.02 1.06 .96 .99 .95 1.02
Ptprr
KLA  ATP  ATP+KLA
 NM_011217 protein tyrosine phosphatase, receptor type, R (Ptprr), mRNA [NM_011217] KLA .97 1.04 1.00 .96 .99 .98 1.02
ATP .96 1.02 .96 .98 .99 .98 .98
KLA/ATP .98 1.04 1.02 1.01 .95 .96 1.00
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rap1a
KLA  ATP  ATP+KLA
 AK030897 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830450G12 product:RAS-related protein-1a, full insert sequence [AK030897] KLA .83 .80 .92 1.04 1.06 .91 1.06
ATP 1.04 .92 1.11 1.03 1.05 .73 .72
KLA/ATP .83 .81 .97 .75 1.14 .71 .53
Rap1a
KLA  ATP  ATP+KLA
 NM_145541 RAS-related protein-1a (Rap1a), mRNA [NM_145541] KLA .87 .78 .76 .86 .86 .84 1.01
ATP .91 .95 1.33 1.20 1.27 1.04 .81
KLA/ATP .68 .75 .92 .85 1.13 .90 .74
Rap1b
KLA  ATP  ATP+KLA
 M79314 GTP-binding protein RAP1b mRNA, partial cds. [M79314] KLA 2.61 2.95 2.81 2.76 3.07 2.67 1.88
ATP 1.00 1.10 1.00 1.94 1.94 1.72 1.31
KLA/ATP 2.49 2.45 2.03 4.23 3.03 2.60 1.86
Rap1b
KLA  ATP  ATP+KLA
 NM_024457 RAS related protein 1b (Rap1b), mRNA [NM_024457] KLA 2.21 2.35 2.71 2.51 2.86 2.44 1.54
ATP 1.05 .92 .93 1.14 1.30 1.26 1.07
KLA/ATP 2.23 2.15 1.57 2.53 2.16 1.67 1.38
Rapgef2
KLA  ATP  ATP+KLA
 AK037061 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930105G09 product:unclassifiable, full insert sequence. [AK037061] KLA 2.39 1.88 1.69 1.79 1.91 1.73 1.42
ATP 1.10 1.22 1.29 1.61 1.28 1.41 1.15
KLA/ATP 2.62 3.19 3.35 1.61 1.35 1.67 2.05
Rapgef2
KLA  ATP  ATP+KLA
 NM_001099624 Rap guanine nucleotide exchange factor (GEF) 2 (Rapgef2), mRNA [NM_001099624] KLA 13.96 13.30 14.47 15.36 15.40 13.03 6.27
ATP .92 .91 1.07 6.35 8.30 6.34 4.39
KLA/ATP 13.04 12.81 13.27 19.07 15.46 12.66 20.32
Rasa1
KLA  ATP  ATP+KLA
 AK042801 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730025L23 product:unclassifiable, full insert sequence. [AK042801] KLA .85 .88 .86 .82 .86 .85 .92
ATP 1.05 .95 .85 .80 .81 .82 .95
KLA/ATP .94 .88 .87 .85 .86 .83 .91
Rasa1
KLA  ATP  ATP+KLA
 NM_145452 RAS p21 protein activator 1 (Rasa1), mRNA [NM_145452] KLA .37 .38 .36 .36 .33 .35 .57
ATP .96 .88 .54 .42 .23 .23 .70
KLA/ATP .36 .35 .23 .25 .23 .23 .44
Rasa2
KLA  ATP  ATP+KLA
 AK081420 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130016C09 product:unclassifiable, full insert sequence. [AK081420] KLA 1.12 1.06 1.09 1.04 .92 .91 1.19
ATP 1.34 1.69 2.20 1.41 1.41 .97 .97
KLA/ATP 1.10 1.18 1.48 1.09 1.02 .91 .86
Rasa2
KLA  ATP  ATP+KLA
 NM_053268 RAS p21 protein activator 2 (Rasa2), mRNA [NM_053268] KLA 1.28 1.22 .92 .86 .96 .93 1.50
ATP 1.10 1.23 .93 .92 3.23 1.69 1.61
KLA/ATP 1.40 1.43 .87 .95 1.61 1.12 1.50
Rasgrf1
KLA  ATP  ATP+KLA
 BC042449 RAS protein-specific guanine nucleotide-releasing factor 1, mRNA (cDNA clone IMAGE:5367388), complete cds. [BC042449] KLA 1.11 1.11 1.10 1.14 1.10 1.07 1.16
ATP 1.03 1.14 1.26 1.35 1.09 1.10 1.01
KLA/ATP 1.12 1.14 1.13 1.15 .99 1.04 1.43
Rasgrf1
KLA  ATP  ATP+KLA
 NM_001039655 RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1), transcript variant 2, mRNA [NM_001039655] KLA 1.26 1.28 1.28 1.29 1.34 1.26 1.47
ATP 1.03 1.04 1.05 .92 .98 1.18 1.22
KLA/ATP 1.33 1.38 1.28 1.18 1.07 1.18 2.74
Rasgrf1
KLA  ATP  ATP+KLA
 NM_011245 RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1), transcript variant 1, mRNA [NM_011245] KLA 1.02 1.05 1.14 1.06 1.14 1.11 1.08
ATP 1.03 .99 1.00 .91 .94 .99 1.01
KLA/ATP 1.03 1.00 1.14 1.13 .98 1.01 1.53
Rasgrf2
KLA  ATP  ATP+KLA
 NM_009027 RAS protein-specific guanine nucleotide-releasing factor 2 (Rasgrf2), mRNA [NM_009027] KLA .98 .93 1.03 .96 .92 .97 .98
ATP 1.06 .97 .99 1.00 1.01 .94 .91
KLA/ATP .96 .95 .94 .90 .98 .94 .96
Rasgrp1
KLA  ATP  ATP+KLA
 NM_011246 RAS guanyl releasing protein 1 (Rasgrp1), mRNA [NM_011246] KLA 6.54 6.48 7.17 6.75 10.11 12.90 17.38
ATP 1.18 1.35 1.31 1.32 1.76 2.47 1.30
KLA/ATP 5.86 7.13 6.00 5.09 3.36 5.58 14.25
Rasgrp2
KLA  ATP  ATP+KLA
 NM_011242 RAS, guanyl releasing protein 2 (Rasgrp2), mRNA [NM_011242] KLA .99 1.04 1.01 .96 1.02 1.07 1.09
ATP .94 1.02 .98 1.08 1.02 1.04 1.00
KLA/ATP 1.01 1.04 .96 1.06 1.05 1.06 .96
Rasgrp3
KLA  ATP  ATP+KLA
 NM_207246 RAS, guanyl releasing protein 3 (Rasgrp3), mRNA [NM_207246] KLA .13 .11 .11 .12 .10 .07 .05
ATP .82 .71 1.08 .69 .32 .09 .12
KLA/ATP .12 .12 .17 .16 .15 .09 .08
Rasgrp4
KLA  ATP  ATP+KLA
 NM_145149 RAS guanyl releasing protein 4 (Rasgrp4), mRNA [NM_145149] KLA .90 .83 .78 .90 .81 .61 .51
ATP 1.10 1.18 1.10 1.22 1.03 .66 .57
KLA/ATP .88 .92 .85 .98 .89 .69 .70
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Relb
KLA  ATP  ATP+KLA
 NM_009046 avian reticuloendotheliosis viral (v-rel) oncogene related B (Relb), mRNA [NM_009046] KLA 4.39 4.46 3.54 3.47 4.36 3.18 2.72
ATP 1.01 1.07 1.23 2.66 3.23 3.50 1.24
KLA/ATP 4.43 4.52 3.56 4.10 2.85 2.92 3.30
Rps6ka1
KLA  ATP  ATP+KLA
 NM_009097 ribosomal protein S6 kinase polypeptide 1 (Rps6ka1), mRNA [NM_009097] KLA .64 .65 .58 .62 .78 .94 .98
ATP .87 .85 .78 .74 .58 .68 .82
KLA/ATP .59 .52 .55 .50 .50 .63 .77
Rps6ka2
KLA  ATP  ATP+KLA
 NM_011299 ribosomal protein S6 kinase, polypeptide 2 (Rps6ka2), mRNA [NM_011299] KLA 1.67 1.69 1.70 1.29 1.50 1.32 1.40
ATP 1.02 1.02 .99 1.28 3.97 3.73 1.32
KLA/ATP 1.90 1.63 1.74 1.99 2.45 2.84 1.59
Rps6ka3
KLA  ATP  ATP+KLA
 NM_148945 ribosomal protein S6 kinase polypeptide 3 (Rps6ka3), mRNA [NM_148945] KLA 2.00 2.37 2.65 2.59 2.40 1.41 .96
ATP 1.09 1.09 1.17 1.29 1.11 1.63 1.83
KLA/ATP 2.44 2.44 2.63 3.13 1.99 1.66 2.09
Rps6ka4
KLA  ATP  ATP+KLA
 NM_019924 ribosomal protein S6 kinase, polypeptide 4 (Rps6ka4), mRNA [NM_019924] KLA 1.23 1.21 1.39 1.13 1.53 1.38 1.49
ATP 1.23 1.29 .83 1.24 1.10 1.02 .95
KLA/ATP 1.45 1.61 .92 1.70 1.25 1.07 1.25
Rps6ka5
KLA  ATP  ATP+KLA
 NM_153587 ribosomal protein S6 kinase, polypeptide 5 (Rps6ka5), mRNA [NM_153587] KLA .79 .69 .61 .60 .48 .52 .49
ATP 1.14 1.25 1.29 1.14 .77 .70 .56
KLA/ATP .82 .73 .65 .72 .53 .59 .52
Rps6ka6
KLA  ATP  ATP+KLA
 NM_025949 ribosomal protein S6 kinase polypeptide 6 (Rps6ka6), mRNA [NM_025949] KLA .98 1.03 1.06 .99 1.01 1.06 1.01
ATP .96 1.00 .97 .92 1.06 1.01 1.00
KLA/ATP .95 1.01 1.01 .97 1.00 .95 1.00
Rras
KLA  ATP  ATP+KLA
 NM_009101 Harvey rat sarcoma oncogene, subgroup R (Rras), mRNA [NM_009101] KLA .89 .89 .99 .98 1.25 1.48 1.81
ATP 1.14 1.17 1.01 1.61 1.37 1.33 1.40
KLA/ATP 1.09 1.05 1.01 1.34 1.24 1.10 1.27
Rras2
KLA  ATP  ATP+KLA
 NM_025846 related RAS viral (r-ras) oncogene homolog 2 (Rras2), mRNA [NM_025846] KLA 7.72 7.35 7.03 5.47 3.21 1.03 .65
ATP .92 .86 .99 .95 1.86 2.13 .72
KLA/ATP 6.51 6.50 5.94 4.45 3.05 1.72 .75
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Srf
KLA  ATP  ATP+KLA
 NM_020493 serum response factor (Srf), mRNA [NM_020493] KLA .56 .53 .61 .82 1.37 1.04 .70
ATP 1.13 .88 .71 .68 .86 .85 .50
KLA/ATP .61 .51 .46 .42 .82 .99 .47
Stk3
KLA  ATP  ATP+KLA
 AK021111 adult male corpus striatum cDNA, RIKEN full-length enriched library, clone:C030030N07 product:unclassifiable, full insert sequence. [AK021111] KLA .94 .92 1.00 .98 .97 .88 1.00
ATP .84 .91 .90 .83 .95 .94 .92
KLA/ATP .97 .92 .88 .86 .84 .85 .83
Stk3
KLA  ATP  ATP+KLA
 NM_019635 serine/threonine kinase 3 (Ste20, yeast homolog) (Stk3), mRNA [NM_019635] KLA 1.51 1.51 1.59 1.55 1.42 1.23 1.14
ATP .99 1.19 1.00 1.28 .82 1.41 1.01
KLA/ATP 1.42 1.63 1.24 1.61 .90 1.13 .93
Stk4
KLA  ATP  ATP+KLA
 NM_021420 serine/threonine kinase 4 (Stk4), mRNA [NM_021420] KLA 2.16 2.04 1.77 1.64 1.71 1.70 1.37
ATP 1.04 1.05 .96 .91 .93 1.17 1.53
KLA/ATP 2.08 2.13 1.73 1.59 1.25 1.35 1.88
Stmn1
KLA  ATP  ATP+KLA
 NM_019641 stathmin 1 (Stmn1), mRNA [NM_019641] KLA .69 .73 .67 .59 .50 .28 .13
ATP 1.04 1.00 1.12 1.23 1.10 .62 .19
KLA/ATP .67 .70 .88 .81 .74 .44 .19
Taok1
KLA  ATP  ATP+KLA
 NM_144825 TAO kinase 1 (Taok1), mRNA [NM_144825] KLA 1.51 1.38 1.34 1.47 1.58 1.39 1.24
ATP 1.06 .97 .83 .63 1.32 1.77 1.07
KLA/ATP 1.39 1.37 1.21 .90 1.30 1.57 1.56
Taok2
KLA  ATP  ATP+KLA
 AK046145 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230344N16 product:unknown EST, full insert sequence. [AK046145] KLA 1.29 1.22 1.28 1.29 1.36 1.35 1.19
ATP 1.01 1.09 1.18 1.06 1.11 1.32 1.20
KLA/ATP 1.14 1.21 1.41 1.31 1.21 1.16 1.40
Taok2
KLA  ATP  ATP+KLA
 AK129235 mRNA for mKIAA0881 protein. [AK129235] KLA 1.22 1.04 1.15 1.16 1.19 1.28 .84
ATP 1.03 .79 .76 .46 .69 .99 .64
KLA/ATP 1.19 1.13 1.31 .78 1.12 1.07 .88
Taok2
KLA  ATP  ATP+KLA
 BC085152 TAO kinase 2, mRNA (cDNA clone IMAGE:6837633), with apparent retained intron [BC085152] KLA 1.01 1.04 1.03 .92 1.02 1.13 1.04
ATP .94 .91 .80 .97 .99 1.30 .94
KLA/ATP 1.07 .97 1.00 1.07 1.44 1.80 1.15
Taok3
KLA  ATP  ATP+KLA
 AK037817 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130052D22 product:unclassifiable, full insert sequence. [AK037817] KLA 1.87 1.57 1.28 1.38 2.04 1.49 .95
ATP 1.13 1.52 1.02 .98 .74 .94 .92
KLA/ATP 1.81 2.50 2.06 1.84 1.09 1.10 1.28
Taok3
KLA  ATP  ATP+KLA
 NM_001081308 TAO kinase 3 (Taok3), mRNA [NM_001081308] KLA 1.26 1.31 1.39 1.95 1.79 1.71 .97
ATP .89 .76 .56 .46 .38 .56 1.01
KLA/ATP 1.15 1.09 1.03 .81 .76 .72 1.23
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
 NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Tgfbr1
KLA  ATP  ATP+KLA
 NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Tnf
KLA  ATP  ATP+KLA
 NM_013693 tumor necrosis factor (Tnf), mRNA [NM_013693] KLA 13.35 12.76 10.71 9.03 10.64 7.39 8.32
ATP 2.01 2.48 8.27 19.20 9.72 4.09 1.49
KLA/ATP 12.72 15.76 12.73 17.34 5.10 3.61 6.07
Tnfrsf1a
KLA  ATP  ATP+KLA
 NM_011609 tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] KLA 1.74 1.71 1.90 2.16 1.95 1.74 1.16
ATP .95 .83 .55 .41 .41 1.55 1.32
KLA/ATP 1.58 1.49 1.19 1.03 .98 2.02 2.10
Traf2
KLA  ATP  ATP+KLA
 NM_009422 Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] KLA 3.38 3.62 3.49 3.36 3.49 3.39 2.68
ATP .97 1.04 1.00 1.10 1.54 2.40 1.55
KLA/ATP 3.38 3.16 2.93 2.74 2.67 3.11 4.70
Traf6
KLA  ATP  ATP+KLA
 NM_009424 Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] KLA 1.19 1.28 1.34 1.20 1.23 1.23 1.28
ATP 1.06 1.12 .92 1.15 2.46 1.84 1.40
KLA/ATP 1.32 1.37 .89 1.16 1.45 1.49 1.46
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74